Induced pluripotent stem cells: where are we today? by Dénommé, Ginny Michelle
 
 
 
 
 
 
 
INDUCED PLURIPOTENT STEM CELLS:  
WHERE ARE WE TODAY? 
 
 
 
 
 
 
by 
 
 
 
Ginny Michelle Dénommé 
 
 
 
A critical review essay submitted to the department of Chemistry & Biochemistry in partial 
fulfillment of the requirements for the Master of Science (MSc) in Chemical Sciences 
 
 
 
 
The Faculty of Graduate Studies 
Laurentian University 
Sudbury, Ontario, Canada 
 
 
 
 
 
 
©GINNY MICHELLE DÉNOMMÉ, 2015 
 
 
 
 
ii 
 
 
 
 
  
iii 
 
 
 
Abstract 
 
For many years, scientists have been trying to elucidate the molecular mechanisms that convey 
pluripotency and self-renewal to stem cells. With this valuable knowledge, they hoped to 
discover relevant information in the development, growth and regeneration of cells, tissues, and 
organisms that allow organisms to live as long as they do. These characteristics were once 
thought to be present only in embryonic stem cells (ESCs), and a few adult multipotent cells such 
as hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs). Recent studies have 
tapped into the potential of our once thought to be terminally differentiated adult cells to produce 
self-renewable, pluripotentiating cells, now termed induced pluripotent stem cells (iPSCs). This 
critical review will discuss the advantages and limitations of the methods developed to generate 
and characterize iPSCs. Advantages and challenges of the use of iPSCs in applications such as 
research and therapeutics will also be discussed.  
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Introduction 
The ultimate goal of many scientific studies is the discovery of molecular mechanisms that 
convey normal cellular functioning and pathological disease in order to introduce new and 
improved ways to diagnose, treat, and or prevent such occurrences. These studies use many 
different types of cells including different types of stem cells. The advent of induced pluripotent 
stem cells (iPSCs) only ten years ago has revolutionized the way that scientist view somatic cells 
and their apparently limited differentiation potential.   
Since the discovery of iPSCs, there has been an explosion of studies done in order to understand 
the reprogramming process and refine the techniques to characterize and generate these types of 
cells. Many studies also show the use of these cells in basic science, disease modeling, drug 
development and screening, toxicology testing as well as therapeutics. With any new discovery 
comes much scrutiny, especially when the use of this technology is to be considered in the 
treatment of diseases in humans.  
The purpose of this critical review is to shed light on the recent advances in the field of stem cell 
technology with regards to the use of reprogrammable adult human cells in the discovery of 
normal cellular functioning, pathological diagnosis, and therapeutics. A brief introduction on 
stem cells and iPSCs will be followed by a detailed look at techniques used for the 
characterization of these cells. A thorough analysis of the reprogramming techniques available as 
well as their advantages and limitations will be provided. Lastly, the applications of iPSCs as 
well as the limitations of their use will be discussed.  
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Chapter 1 – Stem Cells 
1.1 Stem Cells: Overview  
Stem cells have two main characteristics that distinguish them from other non-stem and germ 
cells. Firstly, they can self-renew for prolonged periods of time when maintained in the 
appropriate environment. Secondly, they have the potential to transform themselves into other 
specialized cell types [1-3], a process known as differentiation. Understanding the mechanisms 
that control and convey these properties is important for understanding the steps and processes 
that occur during development (embryogenesis). During embryogenesis, cells are actively 
proliferating and differentiating in order to produce all the cells, tissues and organs of the 
organism. In adults, stem cells allow the regeneration of cells and tissues, such as skin [4], blood 
[1], bone [5, 6], liver [7], neurons [8, 9], and many more, necessary for proper functioning and 
prolonged existence. Therefore understanding the mechanisms that regulate proliferation and 
differentiation in adults can provide insight on normal aging processes, as well as abnormal or 
diseased phenotypes.  More importantly, this understanding can lead to the development and 
application of more appropriate and effective target-based treatments for diseases.  
1.2 Pluripotency and Differentiation  
From embryogenesis to adulthood, a plethora of different stem cells exist in the body at different 
times with varying potentials for self-renewal and differentiation. In humans, the totipotent stem 
cell has the most differentiation potential of all stem cells. They are the first few cells created 
immediately after fertilization of an oocyte. These cells can create all other cells necessary to 
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produce all three germ layers (endoderm, mesoderm and ectoderm) of the embryo, the 
reproductive cells, as well as all the necessary extraembryonic cells to support the embryo’s 
development (cells of the trophoblast and the placenta)(Figure 1).  Four to five days after 
fertilization of the human oocyte, the cells of the inner cell mass of blastocysts are now 
pluripotent. Pluripotent cells can still differentiate into all three germ layers of the embryo, and 
reproductive cells. However they have lost the potential to differentiate into the supporting cells 
that produce the trophoblast and the placenta [3, 10]. These pluripotent cells are known as 
embryonic stem cells (ESCs). Postnatally, somatic and reproductive stem cells exist. 
Reproductive or germ stem cells will produce gametes and somatic or adult stem cells mature 
into all other tissues. Most adult stem cells are multipotent, and can produce many lineages of a 
particular tissue type [10, 11](Figure 1). An example is the hematopoietic stem cell (HSC) that 
can produce multiple different blood cells from both lymphoid and myeloid lineages [1] (Figure 
2), while others will be oligopotent, producing differentiated cells of only one lineage.  
Long-term stem cells (LT-SCs) do not differentiate but will proliferate indefinitely to regenerate 
a specific tissue for the lifetime of the organism, like epidermal stem cells that regenerate skin 
[12]. Conversely, short-term stem cells (ST-SCs) will self-renew to regenerate a tissue only for a 
limited period of time and then will differentiate into more committed cells such as the 
progenitor. Although progenitors may still be multipotent, giving rise to different lineages, they 
have very limited proliferative activity. These cells very seldom self-renew, and if they do, it is 
limited to one or two cell cycles [13].  One such example is the common myeloid progenitor 
(CMP) that leads to the production of only two other multipotent progenitors: the Megakaryocyte 
and Erythroid Progenitor (MEP) and the Granulocyte and Macrophage Progenitor (GMP)(Figure 
2). Each of these cells will then differentiate into distinct oligopotent precursors that can only  
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Figure 1- The Stem Cell Lineage  
 
(Reprinted from Tyndall & Leblanc 2006 with permission)[11]  
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Figure 2 - Hematopoietic Stem Cell Lineage 
(Reprinted from eBioscience.com 2012, courtesy of Affimatrix Inc. with permission)[14] 
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 produce specialized cells from one lineage (Figure 2). For example, the MEP produces the 
lineage-committed megakaryocyte and the erythrocyte progenitor which in turn produce the 
terminally differentiated platelets and erythrocytes respectively (Figure 2). Fully differentiated 
cells have no self-renewal or differentiation potential. They have a limited life-span during which 
they will accomplish their own specialized functions until they die by natural cell death [15, 16], 
and/or are recycled like the erythrocyte [17]. The regeneration of terminally differentiated cells 
and tissue depends on the balance between the survival, proliferation, differentiation and death of 
the different types of adult stem and differentiated cells within each lineage. When this balance is 
shifted, it can lead to problematic phenotypes, making their study important in understanding 
normal and diseased states 
1.3 Important Stem Cells Discoveries 
The study of stem cells is a growing field. To date, many different types of stem cells have been 
identified and isolated for their use in scientific research and medicine. HSCs were first 
discovered in bone marrow by Till & McCullogh in 1961 during their investigation of the effects 
of radiation on the hematopoietic system[1]. Mesenchymal stem cells (MSCs), named by Caplan 
[18] were discovered and isolated from bone marrow by Friedenstein’s group in 1970 [19]. This 
group as well as many others worked on the characterization of MSC to discover their ability to 
produce many different mesodermal tissues like bone, cartilage and muscle [18, 20-23]. Human 
embryonic stem cells (hESCs) were isolated from the blastocyst stage of embryos and studied by 
Thomson in 1998[3]. Although ESCs, HSCs, and MSCs have been fairly well studied and have 
important applications, their availability and isolation can be difficult. ESCs require the 
destruction of embryonic tissue, while MSC are mostly found in bone marrow [3]. Furthermore 
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MSC do not have a uniquely defined cell surface marker [24]. Other sources of stem cells include 
epidermal stem cells [4], intestinal stem cells [25, 26] as well as stem cells found in umbilical 
cord blood[27]. Recently, stem cells have been isolated from menstrual blood, endometrial tissue 
[28] lactating breast tissue and breastmilk [29]. These more recent findings are of scientific value 
since these sources are more readily available and collectable. This accessibility would allow for 
more thorough stem cell studies to be conducted.  
1.4 Induced Pluripotent Stem Cells 
Recent advances have led to the production of pluripotent stem cells from terminally differentiated 
adult somatic cells rather than the classical stem cells found in embryonic tissue or bone marrow. 
This achievement has been under development since the 1950’s in some vertebrates and is still in 
the midst of being perfected. Attempts began in 1958 when John Gurdon produced viable frogs 
by the partial nuclear transfer of a haploid nucleus of a differentiated gut cell into the pronucleus 
of a female frog [30]. By doing so, he showed the scientific community that differentiated cell 
nuclei have an innate potential to behave like the nucleus of a germ cell. In 1997, Wilmut and his 
group continued this line of work and were successful in producing Dolly, the first cloned sheep, 
from the complete nuclear transfer of an adult mammary cell nucleus into an enucleated oocyte 
[31]. Again, their work showed that differentiated nuclei have the potential to be reprogrammed 
by the appropriate environment. In 2006, Takahashi and Yamanaka revolutionized the production 
of pluripotent stem cells by transforming whole cells by introducing exogenous factors [32]. The 
group used viral transfection technology in order to reprogram adult mouse tail-tip fibroblasts to 
their original embryonic stem cell state [32]. Not only were these cells germ line competent (as in 
Thompson and Wilmut’s experiments)[3, 31], but they exhibited self-renewal capabilities for 
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extended periods of time when kept in the appropriate medium. The group showed that these 
cells, now termed induced pluripotent stem cells (iPSCs), can spontaneously differentiate into all 
three germ layers like ESCs, and can be directed to differentiate into different specialized cells 
(cardiomyocytes and dopaminergic neurons) upon exposure to different factors (bone 
morphogenic protein 4 (BMP4) and PA6 respectively)[32]. The group then repeated their 
experiments to reprogram the first human dermal fibroblasts (HDFs) into iPSCs [33]. Since then, 
scientists have been studying the process of reprogramming and redifferentiation of iPSCs in 
order to discover the most efficient, cost effective, and safest methods of producing the cells 
needed for research and medical applications.  
The chapters that follow will review methods for iPSC characterization, and reprogramming. 
Applications and advantages of iPSC over other stem cells in research and clinical applications 
will also be discussed.  
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Chapter 2 – iPSC Characterization  
To evaluate reprogramming efficiency, scientists must perform an in-depth molecular 
characterization of cells, during and after reprogramming. Since iPSCs are somatic cells that have 
been returned to an embryonic state, iPSCs are essentially tested for their resemblance to ESCs. 
The more the treated cells exhibit ESC-like features, the more fully reprogrammed they are 
considered to be. The International Stem Cell Banking Initiative (ISCBI) has published 
guidelines for banking and supply of ESC lines that are applicable to iPSC lines [34]. They also 
provide suggestions of minimal criteria for the classification (self-renewal, pluripotency, genetic 
stability) and advanced characterization for putative iPSC lines [35].  The bulk of this chapter 
will review the methods available to achieve minimal classification criteria and advanced 
characterization of putative iPSC lines. Advantages and limitations of methods will be discussed 
and other potential methods for characterization will be presented.  A brief explanation of 
reprogramming efficiency calculations will end the chapter.  
Since the reprogramming process is not immediate, identification and characterization of iPSCs 
consist of a series of different assays and tests performed throughout the entire reprogramming 
process. A summary of the timeline for different techniques, and their relative use is depicted in 
Figure 3 [36]. Characterization methods will be discussed in approximately the order shown in 
the timeline. 
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Figure 3 - Diagram of the iPSC Characterization Workflow Starting from the 
Reprogramming Process 
Common characterization studies are found in solid boxes, while less common analyses are in the 
dotted boxes. (Reprinted from Asprer & Lakshmipathy 2015 with permission)[36].  
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2.1 Initial Analysis 
In the early stages of reprogramming, shortly after they have been exposed to reprogramming 
factors, a small number of cells will begin the transformation process. The initial morphological 
changes that occur in these cells allow scientists to identify, choose, and finally reseed them for 
final expansion. Since these cells will be used in the lab afterward, it is important that the testing 
done does not affect their viability, growth or reprogramming. Prior to reseeding, scientists 
usually limit their testing to microscopic analysis of cell morphology, live immunostaining for 
cell-surface pluripotency markers, and possibly testing for enzymatic activity of alkaline 
phosphatase (AP), another pluripotency marker.  
iPSCs can be identified from a feeder-cell layer by their compact organization, well-defined 
borders (Figure 4, Panel E), as well as their prominent nucleoli and limited cytoplasmic space 
(Figure 4, Panel F)[32, 37-39]. ISCBI provides governmentally-funded research labs with images 
of ideal colonies for each cell line, which can be quite helpful for scientists that are new to the 
field [35]. Also, the Human Stem Cell Manual Laboratory Guide contains microscopic images 
and descriptive analysis of the differences between differentiating and undifferentiated cells [40].  
Live cell staining can also be used to identify stem cell-surface markers. This technique allows 
cells to be stained and visualized in culture with minimal effect on the cells themselves [41]. This 
consists of immunostaining with appropriate antibodies for pluripotency cell surface antigens 
followed by microscopic analysis. Minimal criteria proposed the ISCBI are positive staining for 
stage specific embryonic antigens 3 and 4 (SSEA3, SSEA4), keratin sulfate antigens 1-60 and 1-
81 (TRA-1-60, TRA-1-81) [34-37, 42], as well as negative staining for SSEA1 (fibroblast cell 
surface antigen). In negative staining, the absence of cell-surface antigen would represent the  
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Figure 4 - Induction of iPS Cells from Adult HDFs 
[A] Time schedule of iPS cell generation. [B] Morphology of HDF. [C] Typical image of non-ES 
cell-like colony.[D] Typical image of hES cell-like colony. [E] Morphology of established iPS 
cell line at passage number 6 (clone 201B7).[F] Image of iPS cells with high magnification. [G] 
Spontaneously differentiated cells in the center part of human iPS cell colonies. (Reprinted from 
Takahashi 2007 with permission)[37] 
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transition of somatic cell toward a reprogramming cell. Other markers that have been used for 
this negative staining are anti-neuron cell surface antigen (A2B5), cluster of differentiation 56, 
13, and 44 (CD56, CD13, and CD44), ganglioside precursor disialohematoside 2 and 3 (GD2, 
GD3).[43-46]. An enzymatic assay for AP activity is also sometimes performed and 
recommended [35], consisting of treatment of the cells with a AP substrate prior to imaging 
[36](Figure 5, Panel A Live iPSCs). Theoretically, antibodies and substrates are non-toxic, and 
can be washed out prior to reseeding and expansion of the iPSCs, however introduction of 
chemicals into cells always carries the potential of influencing cellular mechanisms.  
Reporter constructs can been used to identify early reprogramming cells. In the early 
experiments, scientists transfected cells with plasmids where green fluorescent protein (GFP) 
gene was inserted upstream of the promoter of pluripotency genes such as F-box containing 
protein 15 (Fbx15) [32],  Tἴr na nƠg (NANOG) [47, 48] or Octamer-binding transcription factor 
4 (Oct4) [49].  When endogenous pluripotency genes begin to be expressed, as in reprogramming 
cells, the fluorescent reporter protein gene is transcribed, and then the mRNA of the fluorescent 
protein is translated. Fluorescence can be visualised under the microscope with the use of 
appropriate filters. The disadvantage of this technique is that reporter genes can integrate into the 
genome affecting the reprograming process itself or the integrity of DNA and the cell. 
Furthermore, NANOG and Oct4 genes are expressed only in late reprogramming [36] and this 
late expression may cause scientists to eliminate an early reprogramming cell populations by 
mistake [32, 50].  
Since the introduction of stains and reporters into cells could affect reprogramming, efforts have 
been made to identify iPSCs based solely on their morphology using computational methods. A 
known automated image classifying program, weighted neighbour distances using a compound  
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Figure 5 - Representative Characterization Panel for a Newly Derived iPSC Line 
The minimum requirement for the characterization of a newly derived iPSC line is to show the 
expression of multiple self-renewal genes through cellular and molecular analyses, to 
demonstrate the ability to differentiate into the three germ lineages, and to confirm normal 
karyotype. [A] In this panel, a newly-derived feeder-dependent iPSC line is characterized using a 
variety of self-renewal markers. Live iPSCs are stained using a fluorescent substrate for AP or 
using antibodies against the positive surface markers SSEA4 and TRA-1-60 and the negative 
surface marker CD44. Images are shown as a merge of the phase contrast with the fluorescence 
channels. Fixed iPSCs are stained with antibodies against the intracellular self-renewal markers 
NANOG, OCT4, and SOX2, along with DAPI as a nuclear stain. [B] Additionally, iPSCs are 
allowed to form EBs and differentiate spontaneously for 21 days, then tested for the ability to 
generate the three germ lineages. The Day 21 EBs are stained with DAPI and antibodies against 
Alpha Fetoprotein (AFP) for endoderm, Smooth Muscle Actin (SMA) for mesoderm and Beta-
IIITubulin (TUJ1) for ectoderm. [C] For the molecular analysis, the feeder dependent iPSCs are 
used to make feeder-free cultures and Day 7 EBs. Gene expression is analyzed using the 
TaqMan® hPSC Scorecard ™ Panel and is compared against a known set of reference samples 
through a data analysis software based on Bock et al.[51, 52]. (Reprinted from Asprer & 
Lakshmipathy 2015 with permission)[36] 
B 
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hierarchy of algorithms representing morphology (wndchrm or WND-CHARM) is a potential 
avenue for iPSC identification [53, 54]. This machine-supervised algorithm automatically 
assesses over one thousand features from a multitude of images in order to create classes of 
images. These features can be grouped into four categories: 1) polynomial decompositions, 2) 
high contrast features, 3) pixel statistics, and 4) textures. Once the classes have been defined, the 
algorithm can automatically classify images based on the similarities to the known classes. 
Yamanaka’s group created a model based on morphological similarities and differences of 
previously identified ESCs, iPSCs, and differentiated cells using this system [54]. Their study 
confirmed that WND-CHARM is effective in discriminating between hiPSCs and non-hiPSCs 
with almost 100% accuracy. Thus far, this is the only non-invasive method that has been 
successful in validating early iPSCs, and could be of significant value for scientists in the future.  
2.2 Secondary Analysis  
Once reprogramming cells have been identified, reseeded and expanded, they will be subjected to 
a more thorough characterization process before use in the lab, registration as iPSC line, and/or 
iPSC banking.  Methods to establish self-renewal, pluripotency, and genetic stability will be 
presented followed by advanced characterization methods [35](Figure 3).  
2.2.1 Self-renewal 
Firstly, cells must be able to go through a minimum of 10 passages in a feeder-dependant manner 
without differentiating in order to be labelled as iPSCs [35]. Self-renewal can also be assessed by 
calculating the doubling time during extended proliferation [37, 55] and compared to the 
doubling time of ESCs of approximately thirty two hours [56].  
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2.2.2 Pluripotency  
Pluripotency can be determined by using a variety of techniques that identify expression of cell-
surface pluripotency markers, and genes, as well as differentiation into the three germ layers. 
2.2.2.1 Marker Analysis 
Minimal requirements for iPSC registration require positive results from different tests. Firstly, 
fixed immunostaining and western blotting of cell-surface markers SSEA3, SSEA4, TRA-1-
60/TRA-1-81, AP, SSEA1
-
 , as well as intracellular pluripotency proteins Oct4, NANOG, Sex-
determining region Y-box 2 (Sox2), zinc-finger protein 42 (Rex1), teratocarcinoma-derived 
growth factor (TDGF)[34] must be accomplished (Figure 5, Panel A Fixed iPSCs). Although 
these are the recommended markers from the ISCBI, groups have performed immunostaining and 
western blotting for other pluripotency markers identified by the ISCI such as gamma-
aminobutyric acid receptor beta 3 (GABRB3), DNA methyltransferase 3B (DNMT3B), and 
human Telomerase Reverse transcriptase (hTERT)[37, 55] and negative staining for CD44. Fixed 
staining provides information about the location of the proteins, whereas western blotting allows 
quantification of protein levels within a cell.  This process is accomplished by denaturing isolated 
proteins with sodium dodecyl sulfate prior to separation according to size by polyacrylamide gel 
electrophoresis (SDS-PAGE). This allows proteins to be identified by their size. Once transferred 
to a nitrocellulose paper, proteins can be stained with appropriate fluorescent antibodies and 
fluorescence can be quantified [57]. Furthermore, bands in the electrophoresed gel could 
potentially be excised and sequenced in order to verify the protein identify [58].  
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The downfall of this technique is that cell preparation requires fixing and permeabilization of 
cells with cytotoxic and carcinogenic agents [59]. Furthermore, western blotting requires lysis of 
the cells in order to isolate the proteins. Therefore, cells used for these procedures are useless for 
reseeding, expansion or further testing.    
Flow cytometry or fluorescence activated cell sorting (FACS) are the most common and 
recommended methods for identification of cell-surface markers, cell-counting and sorting [34]. 
In flow cytometry, cells are placed in a liquid medium and incubated with fluorescently labelled 
antibodies for pluripotency or differentiation markers.  They are then forced through a 
micronozzle under pressure. The nozzle vibrates axially to produce uniform droplets of liquid 
containing one cell.  Prior to being expelled from the micronozzle, the cells pass through an 
argon ion laser beam that excites the fluorescent antibodies. The signal from a fluorescent 
antibody-labelled cell is captured by two detectors (front scatter and side scatter detector). 
Fluorescence signals can be analysed by a computer in order to quantify the number of positively 
stained cells in the solution. In FACS, cells go through flow cytometry process, however the 
droplets are negatively charged as they are released from the micronozzle. Cells exiting the 
nozzle are subjected to an electric field that can deflect cells based on their charge. The detection 
of an above threshold fluorescence read by the detectors, transmits a signal that will ensure the 
electric field is applied in a way to deflect the negatively charged droplets into the appropriate 
containers [60](Figure 6). Cells identified and isolated by FACS can be recultured, and used for 
research as long as they have not been contaminated.   
Young-Tae Chang’s group claim to have discovered a more appropriate staining technique using 
a fluorescent, non-toxic molecule compound of designated yellow 1 (Cdy1) instead of an 
antibody, that selectively stains pluripotent cells[61]. Cdy1 is a rosamine, lipophilic cation with  
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Figure 6 - Diagram Explaining Fluorescence-Activated Cell Sorting (FACS) 
This figure is showing a representation of flow cytometry at the top of each diagram, but also shows how additional equipment can 
enable it to be used for FACS. [A] the sample containing cells is injected in the middle of a fluid sheeth and funneled to give a single 
line of ordered cells. The cells are passed through a laser beam that measures the forward scatter (FSC) and side scatter (SSC). Usually 
this flow cytometry result is sufficient for analytical methods, but for a preparatory cell sorting method (FACS) the cells passed 
through a nozzle that vibrates and results in cell droplets with approximately one cell per drop, this drop is then electrically charged to 
give a negative charge on it. The machine computer calculates (since the distance between the laser and the electromagnets is known) 
when the cell reaches the area between the electromagnets; it will switch them on to divert the cell path so it lands on the correct vial, 
and thus accumulate the sorted cells. In this case the beam detects no fluorescence and therefore sends the droplet of cell into the 
negative sample vial. In [B] the laser beam detects the correct fluorescence and therefore sends the charged cell droplet into the correct 
positive sample vial. (Reprinted from Sabban 2011 with permission)[62] 
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peripheral amines that preferentially stains the mitochondria of mESCs, hESCs and miPSCs as 
opposed to cancer cells, and fibroblasts. Interestingly, this stain was shown to target early 
reprogramming cells prior to the expression of Oct4-GFP construct, and ESC-like morphological 
changes [63]. This stain can be used with FACS in the identification and sorting of iPSCs [64]. 
The efficiency of this stain has yet to be verified in human induced pluripotent stem cells hiPSCs. 
Furthermore, since it has recently been shown to positively stain neural stem cells in the 
subventricular zone and the hippocampus [65], as well as drug-resistant cancer stem cells [61], its 
use would be limited to reprogramming of somatic cells that have shown negative staining for 
Cdy1, such as fibroblasts.  
Some scientists verify pluripotency by measuring the expression level of mRNA of pluripotency-
related genes by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR)[55, 
66], however quantification of mRNA levels of pluripotency genes mentioned above via 
quantitative-RT-PCR (qRT-PCR) is suggested as a minimal requirement for classification of 
iPSC lines [34]. In both cases, mRNA is isolated from cells and reverse transcribed into 
complementary DNA (cDNA) that will be amplified by PCR reaction. In RT-PCR, analysis is 
done at the end of the process by detecting the amplified DNA after separation by 
electrophoresis. These bands can further be quantified by densitometry or phosphorimaging [67]. 
In qRT-PCR, the quantification of mRNA levels is performed throughout the amplification 
process by the continuous measurement of fluorescence. These last two techniques allow scientist 
to quickly analyse the expression levels of a small number of genes associated with pluripotency 
at the same time.  Their use is limited to providing information about gene expression levels only, 
as previous studies have shown that mRNA levels and protein levels do not necessarily change 
proportionally [68-71]. A group studying the effects of Nanog depletion on ESCs revealed that 
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changes in many nuclear protein levels were not consistent with corresponding mRNA level 
changes [72]. More recently, Wang’s study on the transcription/export complex (THO/TREX) 
revealed that mRNA levels of Nanog, Sox2, krüpple-like factor 4 (Klf4) and estrogen-related 
receptor beta (Esrrβ) remained unchanged after knock out of THO complex subunits 2 or 5 
(Thoc2 or Thoc5), while their corresponding protein levels were significantly decreased [73].  
For these reasons, mRNA data should be supplemented by immunostaining and western blotting 
which provide information about localization and protein levels necessary for thorough analysis. 
2.2.2.2 Differentiation 
The second aspect to consider when evaluating the pluripotency of iPSCs is their ability to 
differentiate into the three cell lineages (ectoderm, mesoderm and endoderm). An in vitro method 
to verify pluripotency is the spontaneous formation of embryoid bodies (EBs) [32, 42, 55]. There 
are many different protocols for this assay [74], however the basics remain the same. Essentially 
iPSCs are removed from their feeder-layer, and grown on a medium deprived of pluripotency 
signals, without which they differentiate spontaneously [40]. Once they have formed masses, 
termed EBs, these are dissected, analysed for lineage-specific markers by immunostaining, FACS 
or quantification of lineage-specific mRNA levels by qRT-PCR [32]. Markers used include: beta 
III tubulin (TUJ1) [38, 55] and glial fibrillary acidic protein (GFAP) for neural ectoderm; 
vimentin, smooth muscle actin (SMA) and desmin for mesoderm; and alpha-fetoprotein (AFP) 
for endoderm, [55](Figure 5, Panel C and Figure 7, Panels F - K). EBs can also be dissected, 
stained via Haematoxylin & Eosin (H&E), and analysed for morphological features of different 
tissues like cartilage, bone (mesoderm) or structures like glands (endoderm), gut-like epithelium 
(endoderm) and neural rosettes (ectoderm) [32, 47, 55, 75, 76]. Minimal requirements for the 
iPSCs to be used in further studies are immunostaining for TuJ1, GFAP, and quantification by 
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Figure 7 - Embryoid Body-Mediated and Teratoma Differentiation of Human iPS Cells 
[F–K] Immunocytochemistry of a-fetoprotein (AFP)([F], vimentin [G], alpha-smooth muscle 
actin (α-SMA) [H], desmin [I], betaIII-tubulin (βIII-TUBULIN)[J], and glial fibrillic acidic 
protein (GFAP) [K]. Bars = 200 mm [A and B] and 100 mm [C–K]. Nuclei were stained with 
Hoechst 33342 (blue). [L] Haematoxylin and eosin (H&E) staining of teratoma derived from iPS 
cells (clone 201B7). Cells were transplanted subcutaneously into four parts of a severe combined 
immune deficient (SCID) mouse. A tumor developed from one injection site. (Reprinted from 
Takahashi 2007 with permission)[37]  
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qRT-PCR for a choice of markers from all three cell lineages [34].  
Teratoma formation is an in vivo method of verifying differentiation of iPSCs. iPSCs are injected 
into non-obese diabetic severe combined immunodeficient (NOC/SCID) mice. Lack of immunity 
in the mice allows rapid growth of teratomas that can be dissected and analysed for lineage-
specific markers by the same methods as can be embryoid bodies (immunostaining or qRT-PCR 
of mRNA levels) [32, 37](Figure 7, Panel L). The histological analysis of teratomas is more 
difficult than that of the EBs since the differentiating iPSCs can mesh with surrounding tissue, 
making it difficult to distinguish host cells from injected cells. 
Even though this technique is more laborious than EB analysis, confirming differentiation under 
physiological conditions is more biologically relevant than in vitro methods. The ISCBI strongly 
suggests that this procedure be a standard for characterizing iPSCs [34, 35], however only about 
half of the published ESC and iPSC cell lines have been validated with this assay [77].   
A factor to consider when performing teratoma assay is the site of injection. Although iPSCs are 
usually injected subcutaneously into the dorsal flank of NOD/SCID mice [32, 47, 55, 66], they 
have also been injected into the liver, kidneys, testes, or leg muscle [78]. Studies have shown that 
ESC prefer to differentiate into one lineage over another depending on the site of injection [78-
80]. If iPSCs had lineage-preferred differentiation depending on site of injection as ESCs, this 
could lead to false conclusion about pluripotency during their characterization. If teratoma 
formation is to be a gold standard for pluripotency determination of iPS cell lines, clear protocols 
with specific injection sites would need to be established. 
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Lastly, this assay is usually performed in mice regardless of iPSC origin. It remains unclear if this 
cross-species injection could also be influencing differentiation patterns since there is no ethical 
way of comparing results of hiPSC injection into humans.   
The ultimate test for pluripotency is the establishment of germ-line competency. This requires 
that the cells be injected into blastocyst, implanted in vivo, and left to produce fertile offspring 
[48]. This procedure also allows scientists to verify the formation of complete chimeras that are 
fertile and can contribute to the germ line [48, 81, 82]. This is a significant feature that can set 
apart iPSC colonies, however it cannot be tested in primates such as humans due to ethical issues. 
Furthermore, since it involves the creation of life that may be immediately terminated after birth, 
and is not a necessity for characterization or banking, this technical approach is not common 
practice [34].  
2.2.3 Genetic stability 
Before cells are used for research, and/or clinical purposes, or banked, it is important to verify 
that testing or treatment has not altered their genetic stability (Figure 3). The last suggested 
minimal criterion for iPSCs is that they exhibit normal diploid karyotype. G-pattern karyotyping 
involves staining of the cells’ chromosomes during mitosis (metaphase), with Giemsa’s reagent. 
This technique allows scientists to observe and analyse the number, size, arrangement and 
structure of the chromosomes to detect any abnormalities such as aneuploidy, deletions, 
duplications, and/or translocations [83](Figure 8, Panel A).  Although ISCBI’s minimal 
suggested requirement is a diploid karyotype many groups verify and note other anomalies that 
are present in the lines.  
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Figure 8 - Karyotyping 
[A] iPSCs G-banding of a normal male karyotype in 20 cells analyzed. (From Asprer & 
Lakshmipathy 2015 with permission)[36]  
[B] Twenty-four color karyotyping of hES cells (HUES-2 and HUES-10) and iPS-DF19-9- 
11T.H by M-FISH. The high standard and improved speed of the M-FISH analysis have together 
confirmed the newly identified optimal mitotic arrest and hypotonic conditions to provide a 
significant technical breakthrough for chromosomal analysis of hES and hiPS cells. While 
HUES-10 (passage 37) and iPS-DF19-9-11T.H (passage 29) presented a normal karyotype, M-
FISH analysis on HUES-2 at passage 40 revealed, as well as chromosome 12 partial trisomy, a 
couple of structural abnormalities to include a translocation involving an extra copy of 
chromosome 1q and chromosome 18, and an unbalanced translocation involving chromosomes 
17 and 22  (Reprinted from Moralli  2011 with permission)[84] 
A 
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Spectral karyotyping (SKY) and multiplex fluorescent in situ hybridization (M-FISH) are 
adapted karyotyping techniques that may facilitate karyotyping interpretation (Figure 8, Panel B). 
In these techniques, the chromosomes are hybridized with differently coloured fluorescent probes 
and therefore appear in distinct colours as opposed to the black and white appearance of G-
pattern results [84].   
Comparative genomic hybridization (CGH) array or single nucleotide polymorphism (SNP) 
analysis are also methods that allow for identification of genetic abnormalities in cell lines [34, 
35, 85-87]. Panels A and B of Figure 9 represent simplified models for the CGH and SNP 
analysis [88]. These methods were found to be more efficient at identifying genetic abnormalities 
in hESC and hiPSC lines that could not be detected using G-banding karyotyping techniques [89-
91]. Notably, Dekel-Naftal demonstrated through M-FISH that iPSCs had increased aneuploidy 
rates correlated to their number of passages,  and their CGH array showed a recurrent gain of 
chromosome q1 [91].  Laurent was able to detect deletions and duplications in genes analysed by 
SNP genotyping that had been missed by G- banding karyotyping technique [90]. These studies 
establish the importance of the techniques suggested by the ISCBI in the characterization of 
iPSCs, as well as the importance of repeated genomic monitoring of iPSC lines that will be used 
for research or in clinical applications.   
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Figure 9 - CGH and SNP microarray 
[A] In array CGH, iPSCs and somatic cells are differentially labeled using fluorescent dyes then mixed together and co-hybridized to a 
microarray slide bearing oligonucleotides. Each probe represents a specific locus in the genome. The slide is then scanned and the 
fluorescent of each dye for each probe is measured. Yellow dots indicate genomic segments with equal number for both cell types. Red 
and Green dots indicate the loss or gain of chromosomal material in the iPSC respectively. Analysis software can also plot the probes 
along the length of the chromosome depending on its location and also on, above or below a baseline according to its relative 
fluorescent dye intensity. [B] In SNP array, only iPSCs DNA would be labelled and hybridized. The intensity of each oligonucleotide 
on the array is compared to the intensity of the same oligonucleotide in a set of controls established with the patient’s somatic cells and 
the probes can be plotted along the length of a chromosome depending on its location as well as on the B Allele Frequency plot 
depending on its presence or absence and fluorescent intensity. (Modified from Karampetsou et al 2014 with permission)[88] 
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2.4 Advanced Characterization 
Unlike the initial and secondary analyses of iPSC colonies, which are based on the use of a few 
known markers, advanced characterization involves a broader scale of testing. This testing 
includes high throughput analysis and comparison of the transcriptome and the epigenome of 
multiple iPSC lines in order to gain insight on the internal cellular mechanisms controlling 
reprograming, and also to aid in the development of methods capable of properly identifying 
completely reprogrammed cells.  
2.4.1 Transcriptome analysis 
Transcriptome analysis involves the use of high-throughput techniques that allow generation of 
gene expression profiles for cell lines by analysing and quantifying mRNA levels of hundreds to 
thousands of genes at once. Focused array or q-RT-PCR panels allow the analysis tens to hundreds of 
genes [51, 92-94], while microarrays allow the quantification of thousands of predetermined 
pluripotency genes [66, 95-100]. Although the number of genes tested may vary, these three 
techniques are quite technically similar. They involve the creation of cDNA via RT-PCR from 
isolated mRNA, tagging of the cDNA with Biotin or fluorescent dyes, then hybridization of the 
labelled cDNA with a microarray containing a series of known probes. Excitation of the dyes by 
“laser” allows for the capture and measurement of fluorescence and analysis of up-regulation or 
down-regulation of specific genes. The amount of fluorescence is proportional to the amount of 
dye, hence cDNA, that has hybridized to the microarray probes [101](Figure 10).  ISCBI 
suggests the quantification of gene expression using Taqman low-density array cards (TLDA) 
[35]. These methods are convenient when scientists want to focus on specific genes, however  
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Figure 10 - Principle of cDNA Microarray Assay of Gene Expression 
A complete set of mRNA transcripts (the transcriptome) is prepared from the tissue of an 
experimental treatment of condition [iPSCs]. Complementary DNA (cDNA) reverse 
transcripts are prepared and labelled with a [red] fluorescent dye. A control library is 
constructed from an untreated source [ESCs or somatic cells]; this library is labelled with a 
different fluorescent [green] dye. The experimental and control libraries are hybridized to 
the microarray.  A Dual-Channel Laser excites the corresponding dye, and the fluorescence 
intensity indicates the degree of hybridization that has occurred. Relative gene expression is 
measured as the ratio of the two fluorescence wavelengths. Increased expression or "up-
regulation" of genes in the experimental transcriptome relative to the control will be visualized 
as a "hotter" red "pseudo-colour," and decreased expression or "down-regulation" shows as a 
"cooler" green. Intensity of color is proportional to the expression differential. 
Unchanged, constitutive expression (1:1 ratio of experimental to control) shows as a 
neutral black. (Reprinted from Carr 2013 with permission)[102]   
29 
 
29 
 
they may lead to an incomplete analysis of the cells, since important information relative to other 
non-target genes may be missed. That said, serial analysis using different commercially available 
microarrays of pluripotency and non-pluripotency genes could maximize the data obtained.  
Massively parallel signature sequencing (MPSS) [103-105], serial analysis of gene expression 
(SAGE) [106-108], and RNA-sequencing [109, 110] have also been used to create profiles 
without limitation of predetermined genes of interest. MPSS & SAGE techniques couple RT-
PCR and hybridization to measure mRNA, however DNA fragment size, tag length and DNA 
sequence analysed are determined by the restriction enzymes used to cleave the DNA and make 
the tags. Although the two techniques can provide non-specific mRNA data that could be missed 
by specific arrays, sections of the genome can still be missed since restriction enzymes have 
specific cut sites. Again, serial analysis using different restriction enzymes would be necessary to 
thoroughly investigate gene expression, however this could make for a lengthy process [36]. 
Since using a smaller number of shorter tags in SAGE decreases fidelity of the results [103, 104], 
a modified SAGE, long SAGE, using longer probes, was successfully use in the characterization 
of nine ESCs lines [111]. MPSS has also been used in the characterization of signalling pathways 
activated in ESCs and therefore could potentially enable identification and characterization of 
iPSC colonies [108]. RNA sequencing also allows for a non-specific analysis of total RNA, small 
RNA, microRNA (miRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). This technique 
can provide interesting information from sources not usually analysed by other methods [109, 
112].  
To produce a more complete transcriptome analysis, scientists should utilize a variety of 
techniques that can provide information on many pluripotency-related and somatic-related genes, 
as well as non-coding segments of the genome. 
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Interesting computational tools, for the analysis of large scale experimental data, are being 
developed in order to facilitate identification of iPSCs. Using identical culture conditions for all 
cells types, DNA profiling of over 15 000 genes was accomplished via microarray for 20 
previously derived hESC and 12 hIPSC lines as well as 6 fibroblast cell lines. By comparing each 
line to one another and to a reference ESC line, Bock et al. created reference maps (similarities 
and differences) between the three cell types [51]. Their results showed that iPSCs were more 
similar to ESCs in gene expression profiles than to the 6 fibroblast cell lines examined, and that 
iPSCs showed a higher global deviation then ESCs, but that most of the genes that deviated were 
similar among these two cell types. Using bioinformatics data, they integrated the results into a 
scorecard that could measure the quality of iPSCs lines [51]. They created a deviation scorecard 
with the outlier information and a lineage scorecard with lineage-specific outliers which were 
then incorporated into the “Q-RT-PCR TaqMan® hPSC ScorecardTM assay” used in further 
studies to target self-renewal and differentiation genes [52]. This study was unique in that it 
developed an in silico tool that can aid other scientists in the identification and characterization of 
their iPSC lines. It was also unique because the group maintained culture conditions therefore, 
discrepancies noted between cell lines are attributable to the cells and not the medium in which 
they were maintained. Other computational methods developed by merging experimental and 
bioinformatics data include PluriTest [113], and CellNet [114], which were developed to help 
identify differentiated cells from PSCs.  
Large scale studies like these can help gain insight on cell-specific behaviours during 
reprogramming. In order for these methods to be successful, large working databases of 
experimental and bioinformatics information are necessary. There are many bioinformatics 
databases accessible through PubMed, however not as many experimental databases such as 
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Embryonic Stem Cell Atlas from Pluripotency Evidence (ESCAPE) database [115, 116] which is 
still being kept current (last update in august of 2014). Unfortunately, without scientists to share 
information, these bases cannot grow and may become stagnant.  
Transcriptome analysis can lead to the development of helpful computational methods for 
identification and characterization of iPSCs, however they are not common practice. This lack of 
broad-scale information can be problematic because there is conflicting evidence as to which 
pluripotency markers are efficient for iPSC characterization. Chan’s study indicates that 
expression of TRA-1-60, DNMT3B and REX1 can be used to identify fully reprogrammed 
iPSCs, whereas AP, SSEA-4, GDF3, hTERT and NANOG are insufficient as markers since they 
may appear in incompletely reprogrammed cells [117], yet all of these markers have been 
validated by either the ISCI or the ISCBI [34, 35]. Chan’s study demonstrates the importance of a 
more thorough transcriptomic analysis when identifying and characterizing iPSC lines.  
2.4.2 Epigenome analysis 
Epigenetics is another area of study to be considered when characterizing iPSC lines. It has been 
shown that somatic cells and stem cells have different DNA methylation and histone 
modification (mostly acetylation and methylation) patterns [118-120]. For example, repressive 
Histone 3 Lysine 9 (H3K9) and H3K27 trimethylation (H3K9me
3
) of pluripotency genes is lower 
in ESCs as opposed to their differentiated counterpart [121]. Although iPSC characterization is 
usually based on similarities to ESC features, like common H3K4me
3
 and H3K7me
3
 of Oct 4 and 
Nanog [35, 82, 122], as well as characteristic X-chromosome reactivation in female cells [35, 
92], it has been noted that iPSCs and ESCs have minor epigenetic differences [120, 123, 124]. 
These differences are often thought to be caused by somatic memory (somatic cell epigenetic 
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pattern), however studies showed that somatic memory could only explain a small fraction, 
0,01% to 0.001%, of the patterns exhibited by iPSCs [125]. Many methods exist for identifying 
methylation patterns.  
The simplest methods for analysing DNA methylation patterns are: methylated DNA 
immunoprecipitation (MeDIP) [126, 127], followed by array-based hybridization (MeDIP-ChIP) 
and high-throughput sequencing (MeDIP-seq)[128, 129]. During these procedures, DNA is 
sonicated, and denatured to create small fragments of single-stranded DNA that will be treated 
with an antibody for 5methylcytosine (5meC), then isolated by immunoprecipitateion. In MeDIP-
ChIP, methylated and input DNA are differentially stained and hybridized to arrays and 
quantified for comparison, while in MeDIP-seq, both methylated and input DNAs are sequenced 
and compared [129]. Another method that could be useful in the comparison of iPSCs with 
somatic and ESCs, is MeDIP with array-based comparative genomic hybridization (array CGH) 
[130]. This method couples MeDIP with arrays that target the whole genome as well as specific 
loci to produce a broader view of the methylation patterns.  
The most common techniques to analyse the epigenome are based on bisulphite conversion. In 
direct bisulphite sequencing (DBS) [131, 132], DNA treatment with bisulphite converts cytosines 
(C) to uracils (U), while methylated Cs remain unaffected [133]. DNA is then amplified, 
sequenced, and compared to controls [134, 135]. A more advanced technique called reduced-
representation bisulphite sequencing (RRBS) is based on the same principles as DBS. In this 
method, DNA is first treated with restriction enzyme Msp1 in order to create segments of DNA 
(150-175bp and 175-225bp) that will be separated by electrophoresis, treated with bisulphite, 
amplified then sequenced [125]. Bisulphite padlock probes (BSPP) is a method that is more 
specific than DBS and RRBS since it allows for targeting of specific gene promoters by using 
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probes that are constructed prior to bisulphite treatment [118, 136]. Comprehensive high-
throughput array-based relative methylation (CHARM) analysis [120, 137], makes use of a 
methylation-sensitive restriction enzyme McrBC as well as array technology to create 
methylation libraries for somatic, stem and iPS cells that can be compared. Immuno-based 
techniques are limited by the efficiency of the antibodies used and have been shown to be less 
precise than bisulphite conversion methods [137]. Restriction enzyme methods are also limited to 
the restriction sites in the genome [138].  Furthermore, since CHARM is not biased to the CpG 
islands like immunoprecipitation and bisulphite conversion methods are, it can give a broader 
view of the epigenome.  
Histone modification analysis in iPSCs is usually performed by chromatin immunoprecipitation 
(ChIP)[139]. In this procedure, chromatin is conjugated with an antibody that can recognize 
DNA/protein/RNA complexes that can then be separated by precipitation. These samples can 
then be analysed by PCR, q-PCR (ChIP-PCR/q-PCR) or coupled to next generation sequencing 
(NGS) in ChIP-seq [55, 66, 121, 122, 139, 140].  
Epigenetic studies can also lead to in silico methods for future studies. Bock’s thorough 
transcriptome analysis of iPSCs included an epigenetic analysis by RRBS [51, 125]. Their results 
showed that iPSCs were more similar to ESCs in DNA methylation patterns than with the 6 
fibroblast cell lines tested. As with the DNA profiling patterns, the group was able to create 
scorecards that could be used to identify appropriately reprogrammed iPSCs [125]. 
Since epigenetics studies are limited in iPSCs, the ISCBI does not suggest that epigenetic 
analysis be used as a criteria to classify iPSC lines at this time [35]. Even though iPSCs and 
ESCs have more distinct epigenetic patterns then transcriptome patterns [51], making it difficult 
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to assess reprogramming based on epigenetics, these patterns can help identify preferences and 
limitations for differentiation lineages [125], and may provide insight as to molecules that could 
enhance reprogramming protocols [119, 141, 142].   
2.5 Banking and Extended Use Analysis 
When cells are maintained for a prolonged period of time, experiments may need to be repeated 
to ensure cell line integrity, particularly since studies have shown that the number of passages can 
affect aneuploidy rates and genomic stability [91]. Typical analyses include pluripotency marker 
analysis, EB assay, as well as karyotyping or other genetic stability testing (Figure 3)[143].  
Furthermore, if the iPSC cell lines are to be banked, testing becomes even more elaborate since 
scientists need to ensure that cellular identity can be verified before and after banking. Proper 
testing for contamination of the cell line should also be performed. Human Leukocyte Antigen 
(HLA) typing and microbial testing are usually performed prior to storage and after banking, 
along with other characterization experiments such as marker analysis, karyotyping, and DNA 
profiling.  
HLA typing is a test performed prior to organ transplants in order determine the 
histocompatibility of a donor with the recipient and is therefore done on iPSCs to ensure their 
proper identification prior to cell therapy usage [144-146]. HLA typing can be done in order to 
identify a particular cell line [39, 147] or to identify its histocompatibility with another cell line 
[148]. A series of low and high resolution HLA typing tests are commercially available [149-
152]. DNA profiling, used in the identification of individuals, or in paternity/maternity 
identification [153], could also be used to identify iSPC lines that have been stored. This involves 
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amplification of short tandem repeats (STR) of the iPSCs DNA using STR primers. Once 
amplified, the STRs can be separated by gel electrophoresis and banding patterns can be saved 
for future reference when verifying the cell’s identity after being removed from storage.  This test 
is not common practice, but authors suggest that it could become a quick and efficient method of 
identification since reagents are already commercially available and used in forensic casework 
for identification purposes [154, 155] and have been used for identification of ESC lines [148].  
Josephson’s group also suggested that mitochondrial DNA sequencing could be used to identify 
cell lines as it is already used in identification of individuals [148, 156], however this technique 
has a lower statistical power than STR analysis of nuclear DNA, and has a limited potential for 
excluding identity [156]. 
Microbial testing is also an elaborate process that should be undertaken prior to banking, 
especially if there is anticipation of usage for cell therapies since cross-contamination can lead to 
potential dangers for patients [157, 158], and inaccurate results [159]. Test not only include those 
for fungi, or mycoplasma, for which a series of different methods exist [34, 160-163], but some 
banks may require tests for hepatitis C, human immunodeficiency virus (HIV), human 
papillomavirus (HPV), herpes simplex virus, and human herpes viruses [36]. Prior to utilization 
of previously banked iPSCs, retesting of iPSCs should be performed to ensure 1) identification of 
the cells (via marker analysis, DNA profiling), 2) integrity of the cells (via karyotyping), and 3) 
safety of the cells (via microbial testing)[36].  Cell lines that have been altered or contaminated 
should not be used in further studies or clinical studies.  
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2.6 Reprogramming efficiency  
Once treated cells have been characterized and identified as fully reprogrammed, they are termed 
iPSCs. Efficiency of reprogramming is represented by the number of iPSC colonies that appear 
on a growth plate per number of cells that were seeded (1 x 10
4
 – 5 x 108)[32, 164]. In some 
cases, an efficiency percentage is provided. Often times, efficiency is a relative term comparing 
new results to the original induction experiments performed in mice [32] or in humans [37]. 
Some groups simply indicate if modifications to their protocols have enhanced reprogramming 
compared to their own previous protocols. What is certain of the reprogramming process is that 
as indicated by the low percentage of colonies formed, it is not an efficient process. To date, 
percentages have failed to exceed 11% efficiency, however once established, iPSC lines have the 
approximate doubling time as ESCs [37, 56].  
Another aspect of efficiency is the time needed in order to produce iPSCs. This is not always 
measured in the same manner and is sometimes difficult to compare from one study to the next. 
For example, some authors will give a length of time needed before seeing morphological 
changes on the plates, or when cells were reseeded for expansion [38, 165]. This time period is 
usually within two weeks [37, 48], however some techniques have taken up to 40 days to show 
ESC-like colonies on a plate [165]. Some studies do not indicate time at all [166], and 
unfortunately, total time to characterize and obtain completely reprogrammed usable cell lines is 
not noted in reprogramming studies. All this considered, comparing efficiency of reprogramming 
in terms of time is a difficult task.  
For the simplicity of this paper, when sufficient data is provided, efficiency of reprogramming 
will be shared by two means; the number of colonies (completely reprogrammed) per number of 
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cells plated and by percentage. Although time to reprogram is an important factor to consider 
when working in the lab, since not all studies include all necessary times data to formulate valid 
conclusions, only time differences within the same study may be noted.  
Thus far, techniques for characterizing iPSCs during, after reprogramming, prior to and after 
banking have been detailed. The next section of this paper will review: the variety of somatic cell 
types used in induction experiments, the different factors and small molecules used to reprogram 
or enhance reprogramming, as well as the different methods used to deliver factors that induce 
somatic cell reprogramming. Efficiency of each particular method will be provided when data is 
available.  
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Chapter 3 – Reprogramming Methods  
Since Takahashi and Yamanaka’s first successful induction experiments, the procedure has been 
repeated in different cell types and animal species, using different factors and methods. This 
chapter will summarize the variety of cells and factors used and give a detailed description of the 
different methods of reprogramming developed along with their advantages, limitations and 
efficiencies.  
3.1 Cell Types and Species 
iPSC technology has given much liberty to the stem cell field since scientists are no longer 
restricted to isolating adult stem cells with limited differentiation potential. They can now choose 
from a larger pool of available differentiated cells from the body to produce iPSCs then 
redifferentiate them into the cell lines of interest. The biggest challenge to choosing an adult cell 
for reprogramming is selecting an easily accessible cell that demonstrates a high reprogramming 
efficiency. 
Although fibroblasts (tail tip fibroblast (TFFs), foreskin fibroblast, dermal fibroblast, human fetal 
lung fibroblasts) are the most commonly used cells for reprogramming [32, 37, 38, 42, 55, 143], 
many other cell types have been used to produce iPSCs. These include but are not limited to: 
mouse and human hepatocytes [42, 167-169], adult mouse stomach cells [167], mouse pancreatic 
beta cells [170], neonatal human epidermal keratinocytes (NHEKs)[38], adipocyte stem cells 
(ASCs) [171-173], neural progenitor cells (NPCs)[174-176], astrocytes [177], cancer cell lines 
[178], as well as other commercially available cell lines.  
39 
 
39 
 
Although each cell type was reprogrammed successfully, there are limitations to the use of 
certain cells lines mentioned above. Firstly, using commercially available cell lines removes the 
risk of an invasive procedure, and can give insight on reprograming ability, however the 
experimental information gathered from them may not be clinically relevant if they are not 
species and/or patient specific. Ideally, isolating cells from each patient for testing would ensure 
the highest probability of transferability to the patient. Commercially available cancer cell lines 
could be used in research for disease modeling purposes only, since they have been shown to 
retain pathophysiological features from original cells after reprogramming and differentiation 
[178]. Furthermore, isolation, from a patient, of some of the cell lines mentioned above, would be 
problematic.  Fetal tissue would be impossible to harvest from an adult. Furthermore, harvesting 
of neural progenitor cells and astrocytes would require the use of invasive biopsy techniques that 
could cause irreparable damage to the patient. Hepatocytes, pancreatic β cells, and stomach cells 
could be harvested from a donor, but the procedure involves an invasive biopsy that requires 
medical supervision, anesthesia and may require a significant amount of recovery time [47, 179]. 
Dermal fibroblasts remain the most common source of cells used for induction of human iPSCs 
(hiPSCs) and mouse iPSCs (miPSCs) [32, 37, 38, 48, 166, 180, 181]. Skin punch biopsies are 
considered invasive procedures that require local anesthetic, a medical follow up and also bring 
on the risk of bleeding and infection [182], however the patient can heal more quickly from this 
procedure than a biopsy needed for isolation of cells from visceral organs (ex. hepatocytes and 
stomach cells) [47, 179]. Keratinocytes from skin biopsies have also been shown to be efficiently 
reprogrammed. Interestingly, keratinocytes and fibroblasts can be isolated from the same sample 
simultaneously [143]. This practice could make better use of the cells provided in one sample and 
decrease the need for multiple biopsies.  
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Cells for reprogramming can also be obtained from procedures that would normally discard 
useful tissues. For example, HSCs (sometimes identified as CD34
+
 or CD133
+
 cells) from 
umbilical cord blood [174, 183-188] or amniotic tissue [189-191] that are normally discarded 
after birth have been used to produce iPSCs. The limitation is that they must be harvested at the 
time of birth for future use in order to match the patient. Banking of these cells could also allow 
their use for a recipient for which histocompatibility has been established. Having banked cells 
that have already been characterized would facilitate the process of iPSC production and 
utilization for cell therapies in histocompatible persons. Granulosa cells (normally discarded) 
retrieved from the egg follicles of women undergoing infertility treatment [192] are another 
example of cells that have been used to produce iPSCs. Although the fertility treatments are 
invasive, harvesting of the cells does not add to the procedure, and the possibility of banking 
granulosa cells could provide a potential access point for histocompatible recipients with no other 
options. iPSCs have also been produced using the human dental pulp progenitor/stem cells [193] 
isolated from the dental pulp of the third molar, also known as a wisdom tooth [194, 195]. In 
most cases, removal of wisdom teeth is a relatively standard procedure, for which isolation of the 
stem cells post-removal would not add to the recovery time. Lastly, human foreskin fibroblasts or 
keratinocytes used for iPSC production [143] could be harvested from the foreskin normally 
discarded after the surgical or non-surgical circumcision shortly after birth or in adulthood.  
The best option for cell harvesting is obtaining cells in a non-invasive fashion. Obtaining a 
peripheral blood sample is a relatively simple procedure that usually takes less than a minute, and 
requires no medical follow up. iPSCs have been produced from a mixture of the mononuclear 
[196-198], B-lymphocytes alone [199], and T-cells alone [187, 200] isolatable from a simple 
blood sample.  Adult keratinocytes from plucked hair have also been reprogrammed [143, 201]. 
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Since humans can shed up to 200 hairs a day, this source of cells is abundant. Most interesting, 
urine-derived progenitor cells (UDC) from a simple 100mL urine sample [202] have been used to 
produce iPSC lines [203, 204].  Since humans can produce up to 2L of urine a day which can 
contain from 2000- 7000 cells [205], this is also a good source for obtaining reprogrammable 
cells. These are three excellent examples of non-invasive methods of obtaining reprogrammable 
cells from a patient. Since they are not invasive, they could also be easily donated from the 
general public in order to conduct broad-scale studies on iPSC reprogramming or disease 
modelling.  
Unfortunately, accessibility does not necessarily correlate with high reprogramming efficiency. 
Table 1 lists some of the reprogramming efficiencies by cell type. Efficiency comparisons are 
difficult to make since the methods used varied from one cell type to another. From the studies 
listed, we can see that HDF are the cells with the highest efficiency of reprogramming, reaching a 
very high 11% [206]. It would be interesting to see the efficiency of this same method in 
reprogramming more easily obtainable UDC, mononuclear cells or keratinocytes from plucked 
hair. Some reviews claim that terminally differentiated cells are more resistant to reprogramming 
than adult progenitors; however it is difficult to come to this conclusion with the diversity of 
results from different studies. More thorough, wide-scale investigations of a variety of cells using 
identical culture conditions and methodology would be necessary in order to determine the most 
easily reprogrammed cell type. For example, Giorgettii et al in 2009, showed that their method 
could reprogram CD133
+
 cells, while it was inefficient for the more commonly used fibroblasts 
and keratinocytes [183]. Zhu’s and Panopoulos’ studies both showed that their methods were 
more efficient in reprogramming human umbilical vein endothelial cells (HUVECs) than adult 
keratinocytes and amniotic fluid derived cells [207, 208](Table 3.1). Efficiency comparisons  
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Cell type Species Efficiency Accessibility Reference 
Adult stem/progenitors 
Adipocyte stem cells 
(ASCs) 
Human 0.0002-0.02% (1/5x103 cells-1/5x105 cells) Very invasive  Aoki 2010 [172] 
 
Neural progenitor cells 
(NPCs) 
Mouse 
Mouse 
 
 
 
 
Mouse  
Mouse 
Mouse  
0.014%  
0.11% - 0.36% (counting only GFP+ cells/ cells 
calculated to be efficiently transfected and not 
clones/cells seeded)  
0.004-0.006%   
 
0.034% 
0.0125% 
0.001- 0.002% 
Patient derived 
Impossible 
 
Nasal swab 
slightly invasive 
Kim J.B. 2009 [209] 
Kim J.B. 2008 [175] 
 
 
Kim 2008 [175] 
 
Shi 2008 [210] 
Silva 2008 [211] 
Eminli 2008 [174] 
Dental pulp progenitor 
cells 
Human  0.03 – 0.085% (no colony numbers noted, 
article states a few colonies, and # of cells 
seeded. To obtain the lesser % noted, 
there would have to be 900 colonies 
formed / 3 x 104 cells) 
Does not add 
to invasiveness 
of procedure 
Takeda-Kawaguchi 2014 
[193] 
Urine-derived progenitor 
(UDP) cells 
Human 0.1 – 4% (# of colonies seen not given)  
(# of colonies picked (2-11) and # of cells 
seeded (5 x 104) gives 0.008-0.02%) 
Non-invasive Zhou 2011 [203] 
Mesenchymal stem cells 
(MSC) from bone marrow 
Human  0.07% (7 colonies/ 1 x 104 cells seeded) 
 
Very invasive Streckfuss-Bömeke 2013 [201] 
CD34+ (HSC) cells from 
umbilical cord blood 
CD133+/CD34+ (HSC) cells 
Human 0.9% (90 colonies/1 x 104 cells) 
0.09% (49 colonies/5.5 x 104 cells) 
0.45% (#colonies unknown/104 cells) 
Non-invasive Meng 2013 [186] 
Okita 2013 [187] 
Giorgetti 2009 [183] 
Adult Somatic Cells 
Fibroblasts 
Human fetal lung 
fibroblasts 
Human 0.01% (10/1 x 105 cells) Impossible  Warren 2010 [38] 
Dermal fibroblasts 
 
Human 
Human 
Human  
Human 
Human 
0.01% (10/1 x 105 cells) 
0.02% (10/ 5x104 cells) 
0.14% (14/1 x 104 cells ) 
11% (11 579/1 x 105 cells) 
0.14% (#colonies unknown/104 cells) 
invasive Warren 2010 [38] 
Takahashi 2007 [37] 
Strechfuss-Bomeke 2013 [204] 
Anokye-Danso 2011 [206] 
Giorgetti 2009 [186] 
Foreskin fibroblasts Human 
Human 
0.01% (10/1 x 105 cells) 
 
Moderately 
invasive 
Warren 2010 [38] 
Aasen 2010 [143] 
Human fetal skin 
fibroblasts 
Human 0.01% (10/1 x 105 cells) Invasive 
 
Warren 2010 [38] 
Tail tip fibroblast (TTF) Mouse 
Mouse  
0.0016% (13/8 x 105 cells) 
0.04% (# of colonies unknown) 
Invasive 
 
Takahashi 2006 [32] 
Eminli 2008 [177] 
Mouse embryonic 
fibroblasts 
Mouse 0.02% (160/8 x 105 cells) 
0.14 – 0.35% (# of colonies unknown) 
0.1 – 0.3% (# of colonies unknown) 
0.11% (# of colonies unknown) 
9.14% (1600 colonies/1.75 x104 cells) 
Invasive 
 
Takahashi 2006 [32] 
Li 2012 [212] 
Judson 2009 [213] 
Moon 2011 [214] 
Anokye-Danso 2011 [209] 
Keratinocytes 
Keratinocytes from 
plucked hair 
Human 
 
 
 
Human 
A few colonies from 1 plucked hair (no 
other numbers provided) 
0.05% (5 colonies/1 x 104 cells seeded) 
 
No numbers provided (increase 3.5 fold by 
adding small molecules) mention a few 
colonies that were expanded 
Non-invasive Aasen 2010 [146] 
 
Strechfuss-Bomeke 2013 
[204] 
Petit 2012 [215] 
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Keratinocytes from 
human foreskin 
Human  
 
Human  
0.08% (8 colonies/ 1 x 104 cells seeded) 
 
100x more efficient then fibroblast  
a few hundred colonies (300 as opposed 
to 4 with fibroblasts) but no other cell # 
provided) 
Mildly invasive Ruiz 2010 [177] 
 
Aasen 2010 [146] 
Adult human epidermal 
keratinocytes (AHEKs) 
Human 
 
0.45% (#colonies unknown/104 cells) 
0.0003% (3/1x106 cells) 
 
1x efficiency of HUVEC cells from same 
study 
Invasive Giorgetti 2009 [186] 
Zhu 2010 [207] 
 
Panopoulus 2011 [211] 
Other Somatic Cells 
Stomach cells Mouse  No colony or cell numbers provided 
0.01% 
Invasive Aoi 2008 [167] 
 
Astrocytes Human  0.07 and 0.1% (7 & 10 colonies/1x104 
cells) 
Very invasive   Ruiz 2010 [180] 
Granulosa cells Human  0.1% (100 colonies/ 1x105 cell) Does not add 
to invasiveness 
of procedure 
Chuang 2015 [192] 
Mononuclear cells 
     
T-lymphocytes 
    
B-lymphocytes 
Human  
 
Human 
 
Human  
Efficiency numbers unavailable 
 
0.004 – 0.1% (42/1 x 106 – 101/1 x105 
cells) 
0.002 – 0.01% (number of colonies and 
cells not provided) 
Mildly invasive Churko 2013 [198] 
Hubbard 2014 [196] 
 
Okita 2013 [187] 
 
Choi 2011 [199] 
Hepatocytes Mouse 
 
Mouse  
0.0001 – 0.0029% (1-29/ 1 x 106 cells) 
 
0.01% (# of colonies unknown) 
Very invasive Okita 2008 [42] 
 
Aoi 2008 [170] 
Pancreatic beta cells Mouse 0.16% (4/2500 cells) 
(Should be 4/4 x 104) they considered how 
many cells they believed were actually 
transfected from the 40 000 cells – 2500 
Very invasive Standfeld 2008 [170] 
Cancer cell lines Human 
 
Human 
Numbers not available 
 
2-5% (# of colonies unknown) 
 
Commercially 
available non-
invasive 
Patient-derived 
very invasive 
Moore 2015 [178] 
 
Lin 2008 [216] 
Adipose stromal cell Mouse 
 
Human 
0.0001% (# of colonies unknown) 
 
0.0002% (# of colonies unknown) 
Invasive Miyoshi 2011[217] 
Neonatal epidermal 
keratinocytes 
Mouse 0.01% (10/1 x 105 cells) Invasive  Warren 2010 [38] 
Neonatal human 
epidermal keratinocytes 
(NHEKs) 
Human  0.0004% (4/4x106 cells) – 0.104% 
(104/1x105 cells) 
Invasive Zhu 2010 [210] 
Human umbilical vein 
endothelial cells (HUVECs) 
Human 0.0035% (7/2x105 cells) 
0.012% (23/2x105 cells) 
2.5 – 3% higher than keratinocytes from 
the same study 
Non-invasive Zhu 2010 [210] 
 
Panopoulos 2011 [208] 
Amniotic fluid derived 
cells (AFDCs) 
Human  0.0011% (11/1x106 cells) Non-invasive Zhu 2010 [207] 
Table 1 - Reprogramming Efficiencies of Different Cell Types 
44 
 
44 
 
would also need to be species-specific since it has already been shown that handling as well as 
reprogramming techniques in different species must be adapted [37]. Lastly, efficiency is not the 
only factor to consider when choosing a cell type. If the cells are going to be used for cell 
therapy, patient-derived cells are more clinically-relevant, and the least invasive method should 
be used to obtain them in order to avoid trauma to the patient, even if the reprogramming 
efficiency may not be quite as elevated.  
Since most studies to date have been completed in mice and humans [218], most of the methods 
discussed will have been conducted using mouse or human cells. It is worth mentioning that 
some iPSC studies have been conducted in pig  [219, 220], rabbit [221], rat [222] marmoset [223, 
224] as well as rhesus monkeys [225-227], Pigtailed macaque [228] cynomolgus monkey [229, 
230], and chimpanzees [66, 231].  
Next we move on to evaluate the different methods that have been used in order to reprogram 
somatic cells. This will include looking at different transcription factors, methods, small 
molecules, microRNAs, and bacteria used to create iPSCs. 
3.2 Reprogramming Factors  
In order to attempt the reprogramming of somatic cells to an embryonic state, it is imperative to 
understand the properties of ESCs as well as the factors that regulate their pluripotency and self-
renewal. The elucidation of these factors over the years was key in the first induction experiments 
and will briefly be discussed. mESCs were isolated and cultured for the first time in 1981 by 
Kaufman’s and Martin’s groups [232, 233], while hESCs were only isolated in 1998 by 
Thompson’s group [3].  Although many differences exist between the two cell types, both share 
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the same core pluripotency factors, notably, Oct4, Nanog, and Sox2 [92, 234-236] (Figure 11). 
Oct4 encodes for a transcription factor (TF) that belongs the POU homeodomain DNA binding 
family [237] that must be tightly regulated to ensure pluripotency and self-renewal, as an increase 
or decrease by half will induce differentiation into either trophoectoderm or primitive 
endo/mesoderm respectively [238, 239]. Sox2 TFs have the high mobility group (HMG) DNA-
binding domain, known for its importance in the later stages of embryogenesis and in neural 
progenitor self-renewal [33, 240]. Oct 4 and Sox2 have shown to bind together to regulate 
transcription of other pluripotency genes such as Fbx15, fibroblast growth factor 4 (Fgf4) and 
undifferentiated embryonic cell transcription factor 1 (Utf1) [241-244]. Nanog is also part of the 
homeobox domain TFs essential to pluripotency as Nanog-deficient ESCs differentiate [245]. 
These three TFs have been shown to bind one another to regulate their own promoters, forming 
an auto-regulatory loop [246, 247](Figure 11). They also co-operate to promote the expression of 
other genes responsible for pluripotency, self-renewal and proliferation such as: krüpple-like 
factor 4 (Klf4), cellular myelocytomatosis (cMyc), signal transducer and activator of transcription 
3 (Stat3), Klf2, sal-like protein 4 (Sall4), Rex1, dosage-sensitive sex reversal, adrenal hypoplasia 
critical region, chromosome X, gene1 (Dax1), transcription factor 4 (TCF4), Sox18, zinc-finger 
protein 281 (Zfp281), and repress differentiation genes [236, 246-253] (Figure 11).  
Although mESCs and hESCs have been studied extensively since their isolation, and we now 
know much about the regulation of their pluripotency and self-renewal, much of this information 
was not available prior to the first induction experiments. As experiments were performed to 
reprogram cells, more knowledge was gained pertaining to the efficiency, safety, and necessity of 
different factors.  
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Figure 11 - Schematic Representation of the Transcriptional Regulation of Core 
Pluripotency Factors and the Extended Factors 
 
(Reprinted from Bieberich and Wang 2013 with permission) [254] 
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In the initial experiment, Takahashi and Yamanaka selected 24 genes to test based on previous 
experiments showing their involvement in pluripotency, self-renewal, and/or cell survival [32]. 
They developed an assay that would allow them to determine which factors were primordial in 
creating iPSCs. This system consisted of inserting a beta geo (βgeo) cassette into the promoter of 
the proliferation-associated gene Fbx15. This cassette included the β-galactosidase as well as the 
neomycin resistance gene. Insertion of this reporter construct into the cellular DNA, allowed 
scientists to identify cells with an active Fbx15 promoter (reprogramming cells) by 5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside (X-gal) staining of gentamycin resistant cells [32]. With 
their system, individual withdrawal testing identified 10 factors necessary for reprogramming. 
Subsequent single factor withdrawal experiments led to the identification of four primordial 
inducing factors. These have now been termed the four Yamanaka factors and consist of; OCT4, 
Sox2, cMyc, and Klf4, two core pluripotency factors, and two secondary factors known to 
regulate proliferation. These factors produced iPSCs with an efficiency of 0.0016-0.02% (13 
colonies/8x10
5
 cells -160 colonies/8x10
5
 cells) using mouse embryonic fibroblasts and tail tip 
fibroblasts [32] and 0.02% (10 colonies/5x10
4
 cells) using human dermal fibroblasts [37]. These 
four factors have acquired the abbreviation (OKSM) and their use in different studies has been 
cited multiple times in many reviews [179, 218, 255, 256]. Many other factors have been used in 
reprogramming. At approximately the same time as Yamanaka’s group, Thompson’s group 
successfully reprogrammed human fibroblasts using their four factors; OCT4, Sox2, NANOG 
and lineage protein 28 (LIN28), selected from their initial 14, with 0.022% efficiency (198 
colonies/9x10
5
 cells) [50]. These include three core proliferation factors and LIN28, which 
encodes a microRNA-binding protein that inhibits processing of microRNA (miRNA) in ESCs 
[257]. Shortly after, an extensive study was done, showing that Sox2, Klf4, cMyc could be 
replaced using family members, Sox1, Klf2 or Klf5, lung-Myc (LMyc) or neuroblastoma-Myc 
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(NMyc) respectively [47] to produce iPSCs with different efficiencies. The use of cMyc and 
Klf4, however have revealed to be problematic. Following germ-line competency testing of 
iPSCs, it was discovered that the cMyc transgene reactivation, a known oncogene, was 
responsible for the production of tumors in mouse pups [48]. Furthermore Klf-4 is also an 
oncogene associated with the pluripotency, and migration of cancer cells [258]. Member of the 
Klf and cMyc family used in Nakagawa’s study are also oncogenic and carry the same potential 
dangers [259, 260]. The use of any of these oncogenes is a safety concern for cells that would 
potentially be used in clinical applications. For this reason, production of iPSCs by transfection 
of OS, LIN28 and NANOG are more suitable for cells that may be used in clinical applications. 
Efforts to identify non-oncogenic factors, led Nakagawa’s group to modify their initial protocol 
and produce iPSCs with only OKS [47]. Giorgetti et al were also successful in inducing iPSCs 
utilising only SOX2 and Oct4 factors, although at much lower efficiencies (0.00625%: 5 
colonies/8x10
4 
cells)[183].  
The most frequently used factors remain OSKM, LIN28 and NANOG [261], however other 
factors have been identified to either enhance reprogramming with these most common factors or 
to replace one or several of them. For example, Sall4 is part of a TF family known for their 
cysteine 2 histidine 2 (C2H2) zinc-finger motifs suggested to contribute to the maintenance of 
pluripotency in ESCs by regulation of Oct4 gene expression [262, 263]. Sall4 co-expression with 
OSK, showed a 2 fold increase of production of iPSCs (0.15% - 300 colonies/2x10
5
cells) from 
fibroblasts as compared to OSK alone (0.08% -160 colonies/2x10
5
cells)[264]. Glioma-associated 
oncogene similar transcription factor 1 (Glis1) was used to enhance OKSM (0.074%- 37 
colonies/5x10
4
 cells) as well as replace cMyc (0.07% - 35 colonies/5x10
4
 cells) in 
reprogramming [265]. Nuclear receptor 5a2 (Nr5a2) was used with SKM (0.024%- 24 
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colonies/1x10
5
 cells) or SK (0.003% - 3 colonies/1x10
5
 cells) to produce iPSCs [266], while 
Esrrβ was used to replace Klf4 and cMyc in OS reprogramming (≈ 80 colonies)[267]. E-cadherin 
(E-cadh) was also used to replace Oct4 in KSM reprogramming [268].  Authors note the 
decreased efficiency in reprogramming; however they did not provide colony or cell numbers. 
Sall4, Esrrβ, and LIN28 were used in combination with developmental pluripotency associated 
factor 2 (Dppa2) or Nanog and produced iPSCs [269]. More recently, Bugamin also showed that 
Sall4, NANOG, Esrrβ and LIN28 (SNEL) could be used to reprogram somatic cells albeit less 
efficiently (0.001-0.005% - 1-5 colonies/1x10
5
 cells) than the OKSM factors [76]. The group 
went on to show that cMyc and Klf4 caused genomic instability, since they are responsible for an 
increase in gamma histone 2AX (γ-H2A.X) phosphorylation, a marker for double stranded DNA 
breaks [270].  
It is clear that reprogramming efficiency varies with the use of different factors; however it is 
unclear that this is the only variable implicated since the methods and cell types used in the 
studies mentioned were not consistent and may also affect results. Studies showing negative 
effects of TFs like cMyc and Klf4 bring up safety concerns associated with choosing factors for 
reprogramming. Although OKSM factors are commercially available for reprogramming with 
many different methods (which will be discussed shortly), possible negative effects, as well as 
future use of the cell lines need to be considered before choosing reprogramming factors.  The 
safety of the factors needs to be considered especially if cells will be later used in a clinical 
setting. Furthermore, since using different cell lines or exposing cells to different factors could 
potentially generate different results, using identical cells and factors in both the laboratory cell 
lines and clinical cell lines would increase the transferability of lab results to a clinical setting.  
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3.3 Delivery Methods  
While some groups work on identifying easily obtainable and reprogrammable cells and/or safe 
and efficient TFs, much work has been done to introduce different methods by which to deliver 
these factors to different cells. Since the initial induction experiments [32], a variety of methods 
have been developed and used to reprogram somatic cells to an embryonic state. This section will 
describe the principles behind the techniques currently in use, as well as their advantages and 
disadvantages. These include a variety of viral, non-viral DNA, and DNA-free delivery methods, 
as well as small molecules, and miRNAs identified for enhancement or de novo reprogramming. 
Lastly, a bacterial reprogramming method recently discovered will be presented.  
3.3.1 Viral Delivery Methods 
3.3.1.1 Integrative Viral Methods 
The first induction experiments were completed by retroviral transduction (Figure 12) of OKSM 
factors by Yamanaka’s groups [32, 37, 48]. Their pMXs-gw vectors are based on the Maloney 
murine leukemia virus (MMLV). At approximately the same time, Yu’s group did their first 
induction experiments using lentivirus’ [50](Figure 12), which are commonly derived from the 
human-immunodeficiency virus (HIV)[255]. Both of these viral systems infect in approximately 
the same manner, however retrovirus are only taken up by replicating cells while lentivirus can 
be incorporated into dividing and non-dividing cells [255, 271, 272]. They are recognized by the 
host cell via cell-surface receptors, and then internalized. Reverse transcription into cDNA of the 
viral RNA is achieved via their own retrotranscriptase, after which the cDNA is shuttled into the 
nucleus (Figure 12).  Prior to integration into the host genome, the viral cDNA  
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Figure 12 - Viral Methods in Reprogramming 
(Modified from Gonzalez et al. 2011 with permission)[255]  
Sendai Virus & 
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undergoes a deletion of its 3’ untranslated region (3’UTR) region, the 3’ long terminal repeat 
(LTR) and internal promoter rendering it self-inactivated and incapable of self-expression [271]. 
Since these viruses lack their replication machinery and 3’ promoter, they will not replicate and 
produce new viable viruses, but their cDNA can be expressed by the host machinery using the 
viral promoter in the 5’UTR region of the virus [273, 274]. They may be transcribed multiple 
times before being silenced through a variety of host epigenetic silencing mechanisms [275]. 
Although these methods are effective in producing iPSCs (0.02% retroviral system [37] and 
0.022% lentiviral system [50]), viral transgene integration is permanent [276], causing changes in 
copy number variation and genomic instability. It was established that each iPSC clone had 3-6 
retroviral integrations for each factor transfected [37]. Although epigenetically silenced, their 
permanency opens the possibility of reactivation of the transgenes, which is especially 
problematic in the case of oncogenes cMyc and Klf4 that could induce tumorigenesis [48].  Even 
in the absence of oncogenes, like in the case of induction with OS, LIN28 and NANOG, 
integration can still disrupt expression (downregulate or upregulate) of nearby genes [255].  
3.3.1.2 Inducible Viral Methods 
To address transgene reactivation, a Doxycycline (DOX)-inducible lentivirus was 
produced by replacing the ubiquitin C promoter of the plasmid with a tetracycline operator 
(tetracycline response element (Tet)) also known as a doxycycline (DOX)-inducible promoter 
and minimal cytomegalovirus (CMV) promoter [170, 277-280] (Figure 12). Only cell cultures 
treated with DOX are successfully transformed into iPSCs. After removal of doxycycline, 
transgenes are no longer expressed. Furthermore, studies showed that decreased expression of 
these transgenes allowed for a better differentiation potential after reprogramming [277]. 
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Although this technique addresses reactivation concerns, it does not address genomic instability 
from viral transgene integration.  
3.3.1.3 Excisable Viral Methods 
In order to address the genomic instability caused by these first two methods, excisable viral 
methods were developed. Cre-recombinase excisable lentivirus have been developed [234] by 
inserting LoxP sequence into the 3’ deleted untranslated (dU3) long terminal repeat (LTR) region 
of the lentivirus. During reverse transcription of the viral RNA, the 3’ loxP sequence is replicated 
and inserted into the 5’ LTR, rendering the inserted transgenes “FLOXED” with loxP sites on 
either side. Two groups showed that generation of iPSCs was successful after transfection with 
the Cre-loxP lentiviruses [234, 281]. iPSCs are then treated with Cre-recombinase, either by 
transfection of an adenoviral vector expressing Cre-recombinase [281], a Cre-encoding plasmid 
[278],  Cre-mRNA [282] or even Cre-protein [234]. Cre-recombinase is an enzyme that 
recognizes and binds to a 34 base pair sequence in the FloxP repeat, then excises the floxed gene 
[283]. Successful removal of transgenes is confirmed by PCR amplification [234, 281] and/or 
Southern  blotting of particular transgene sequence within the iPSCs DNA [281].  This system 
has been used to produce iPSCs with higher efficiency (0.5% - colony numbers not given) [280] 
than the retroviral system (0.02%)[37]. Other than avoiding transgene reactivation, excision of 
the transgene increases differentiation potential of the iPSC colonies [281]. A DOX-inducible 
Cre-excisable lentivirus system expressing OKSM (also known as STEMCCA-LoxP vector) was 
also developed [234, 278, 280, 281], and showed to produce hiPSCs that have gene expression 
profiles more similar to those of hESCs than other hiPSCs produced by retroviral transfection 
with the same four factors, suggesting a more complete reprogramming [278].  Although the 
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removal of the transgene is an improvement on the previous viral delivery methods, it can still 
create genomic instability since the loxP sites remain integrated into the host genome [283].  
3.3.1.4 Non-Integrative Viral Methods 
There are two non-integrative viral delivery methods available, which are based on the 
adenovirus [42, 284-288], and sendai virus (SeV)[164, 185, 289]. The Adenovirus is a DNA 
virus while the SeV is an RNA virus. Both will be incorporated into dividing and non-dividing 
cells, and produce proteins from their respective nucleic acids independently of the host genome 
while remaining in the cytoplasm. Although adenoviral methods were successful, and without 
tumor formation after transplantation, efficiency is very low (0.0001- 0.001%)(0.0002% - 2 
colonies/1x10
6
cells)(0.0011 - 0.006% - colony numbers not provided)[284, 285, 287]. The 
Sendai viral system was effective in producing iPSCs in a variety of cells (0.001-1%),(0.002-
0.22% - 2-22 colonies/1x10
4
cells)[164, 185]. Non-integration of the viral vectors was confirmed 
by PCR [42, 284, 285] and Southing blotting [185, 284, 285] and absence of viral gene 
expression was confirmed in iPSC colonies by RT-PCR [185]. iPSC production with these two 
systems may be lengthy since cells are sometimes put through a heat treatment to minimize SeV 
expression after induction [185]. Furthermore it may take several passages for cells to be 
completely virus free [185, 285]. However, the adenoviral and SeV methods have shown to be 
the safest viral methods since they address genomic integration and reactivation of oncogenic 
transgenes.  
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3.3.2 Viral Free DNA Delivery Methods 
Non-viral DNA delivery methods of have also been used to reprogram somatic cells. This 
method consists in transfecting linear or circular DNA vectors into the host cell without any other 
viral or bacterial packaging. These include linear viral vector, bacterial episomal non-replicative 
or replicative vectors [42, 166, 290], as well as DNA minicircles [291] [292](Figure 13). 
Theoretically, these vectors do not integrate into the host genome, and are expressed because they 
contain constitutively active promoters. They are degraded and lost by dilution rather quickly, 
and may need multiple transfections to induce reprogramming as opposed to the higher 
transfection rate of viral methods. In order to ensure that exogenous factors are expressed, some 
groups use integrative-excisable plasmid vectors (PB transposon and LoxP-Cre)[281, 293] 
(Figure 13). We will first discuss non-integrative, then integrative-excisable vector methods.  
3.3.2.1 Non-Integrative plasmid vector DNA Methods 
Yamanaka’s group created two plasmid vectors from adenoviral sources to produce iPSCs; both 
harbouring a constitutively active CAG promoter [180]. The CAG promoter consists of the 
cytomegalovirus enhancer fused to the chicken beta actin promoter. Their first vector was 
polycystronic, containing three OKS factors separated by a 2A self-cleaving peptide. The second 
contained only the single cMyc factor. Since they are non-replicative, these vectors had to be 
repeatedly transfected in order to induce reprogramming (2 to 4 times each).  Although the PCR 
and Southern blot experiments in 2008 were negative for transgene integration, PCR experiments 
in 2010 confirmed that12 of 15 clones showed positive banding for genomic integration using 
this method [42, 180]. It therefore maintains the genomic instability and transgene reactivation 
concerns of the previous integrative viral systems.   
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Figure 13 - Viral Free Methods in Reprogramming 
(Reprinted from Gonzalez et al. 2011 with permission)[255] 
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3.3.2.2 Non-Integrative Replicative and Non-Replicative Episomal Vector DNA 
Methods 
Replicative and/or non-replicative episomal vectors of bacterial origin have also been used to 
reprogram somatic cells [42]. These plasmids have the ability to replicate and/or express their 
genes autonomously and therefore should potentially integrate less than other plasmid vectors. 
Replicative vectors include the origin of replication/Epstein-Barr nuclear antigen 1 (OriP/EBNA-
1) replication sites, while non-replicative vectors do not. The advantage of replicative vectors is 
that they may decrease the number of transfections necessary to induce reprogramming; however 
they may also increase the time necessary to dilute vectors from iPSCs after reprogramming. 
These vectors have been used to express OKSM factors and modified to allow expression of 
other reprogramming factors [50]. Yu’s original system used a total of three vectors with the 
OriP/EBNA-1 sites which introduced six reprogramming factors in total: Oct3/4, Sox2, cMyc, 
Klf4, LIN28 as well as NANOG [166]. This system was not successful [50] until the group added 
the proto-oncogenic Simian Vacuolating Virus 40 Tag large T gene (SV40LT) to the vector. Its 
role in efficiency is not quite known, but it is postulated that the SV40LT increases 
reprogramming efficiency by inhibiting tumor suppressors such as  p53, p107 and retinoblastoma 
(RB), hence promoting cell survival [290], yet it also counteracts the oncogenic effect of cMyc 
[166, 294, 295] which allows cell survival during reprogramming. Yu’s group also modified the 
vector to allow for drug selection. This allows for quicker, more effective dilution of the plasmid 
from the iPSC clones after induction. Measurements of exogenous mRNA levels via RT-PCR 
experiments after cellular reprogramming confirmed that, in the absence of drug selection, 
approximately 5% of the episomal vectors are lost each cell cycle due to silencing of the viral 
promoter driving EBNA-1 expression. Although PCR experiments showed transgene integration, 
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they also showed that subclones of the original iPSCs had lost this integration, demonstrating that 
subclones may not harbour the same integration concerns as their parental iPSC lines [166].  
In 2012, Meng’s group created a replicative episomal vector that did not require the use of SV40 
or cMyc. It consisted of the Spleen focus-forming virus (SFFV) promoter that had been shown to 
be more efficient in HSCs than other promoters [296, 297]. The vector contained the Sox2 and 
Oct 4 genes, separated by the 2A self-cleaving peptide, the OriP/EBNA1 sites to allow 
replication, and the SV40 poly adenylate (polyA) tail only. This first attempt was unsuccessful in 
producing iPSCs. The group modified the vector by adding the woodchuck transcriptional 
regulatory element (Wpre) after the second gene of interest. This is a technique often used in the 
lentivirus system. This change allowed the group to produce 20 iPSC colonies from 1 x 10
5
 cord 
blood (CB) CD34
+
 cells (0.02%). What was even more interesting is that the group was able to 
induce up to 90 iPSC colonies with two Wpre-vectors containing OS and MK respectively from 1 
x 10
4
 CB CD34
+
 cells (0.9%). These efficiencies surpass Takahashi’s retroviral OKSM system 
(0.02%) as well as those previously stated for all other methods when reprogramming cord blood 
cells [186].  
3.3.2.3 Non-Integrative Minicircle Vector DNA Methods 
Another viral-free DNA method of reprogramming is that of DNA minicircle vectors developed 
by Wu and Longaker in 2010 [291]. This system allowed reprogramming of human adipose stem 
cells (hASCs). Minicircle vectors are essentially the DNA of the reprogramming genes once the 
plasmid backbone (origin of replication, antibiotic resistance cassette) has been removed. Since it 
is smaller and contains only the expression cassette of the reprogramming genes, it is more 
resistant to host silencing than other plasmids, increasing transgene expression and avoiding the 
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need for daily transfections [298]. Since they are still lost by dilution quite easily, cells are 
usually transfected on days 1, 4 and 6 [291]. Minicircles have shown to be more efficient for 
transfection and transgene expression then other full-length DNA plasmids [291, 299]. However 
minicircles containing the four factors (Oct4, Sox2, LIN28 and NANOG) showed an efficiency 
of 0.005% [291] which is much lower than that reported by viral-based methods with the same 
four factors (0.022%) [50]. The benefits of this method are said to outweigh the decreased 
efficiency since the protocols are simple, using a single non-integrative vector, without the use of 
oncogenic cMyc, Klf4 or SV40. These non-integrative, non-replicative, non-tumorigenic 
methods are a good advancement in the field of iPSC production. Furthermore, minicircles are 
FDA approved therefore could have clinical applications [291]. 
3.3.2.4 Inducible-Excisable Vector DNA Methods 
In order to address the repeated transfections necessary with non-integrative and non-replicative 
vectors, inducible-excisable vector systems can be used. The Dox-piggyBac transposon system 
requires the transfection of a minimum of two plasmid vectors. The first vector contains the 
transgenes of interest and two piggybac (PB) transposons, which are short sequences of DNA 
containing two inverted terminal repeat (ITR) sequences upstream and downstream of the gene 
[300-303]. The second vector contains the DOX-inducible promoter with the gene coding for the 
protein transposase. In a first step, both vectors are transfected simultaneously [293, 304]. Upon 
treatment with DOX, the transposase gene will be expressed. Transposase cuts the PB transposon 
at ITR sites, excises the transgene and inserts it into the host genome at specific TTAA sites 
[300]. A second transfection with the PB transposase and DOX treatment, allows for recognition 
and excision of the ITR and transgenes previously inserted leaving the host genome relatively 
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void of the transgene and PB transposon that was inserted [304]. Although this method has 
shown to be effective at inducing iPSCs (0.22% - 1250 colonies/5x10
5
 cells), PB transposase 
insertion and excision activity cannot be specifically controlled. Therefore a second transfection 
of PB transposase could lead to the excision and reinsertion of PB transposon elsewhere in the 
genome [293]. Although this system has shown to allow removal of transgenes from iPSCs, the 
fact that PB transposase preferentially target palindromic TA-rich sequences in the human 
genome remains a concern [305]. Since these sections are known for a higher rate of gene 
expression, integration could have various effects on expression of endogenous genes, 
reprogramming, or other unknown effects on the cells. Furthermore this technique is labour 
intensive and requires many steps not needed in other methods that have been and will be 
described[306].  
As previously discussed with the lentiviral system, the loxP-Cre excisable system can be applied 
to the plasmid vector method or linear DNA fragment method (Figure 13). As a brief review, this 
method consists in inserting loxP segments on either side of the transgene that will allow for 
excision of the transgene upon exposure to Cre-recombinase. Once excised, the transgene 
segments are lost by dilution [255] (and should not pose a threat to the remaining cells), however 
the remaining loxP sites could cause some genomic scaring and instability as opposed to the 
more effective removal by the PB transposon method.  
3.3.3 DNA Free Delivery Methods 
Although the methods mentioned above have been successful in reprogramming cells and 
showing lack of integration, using DNA based methods inherently carry the possibility of 
integration into the host genome. In order to avoid the possibility of integration of exogenous 
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DNA, DNA-free induction methods have been developed. These methods include the use of 
messenger RNA (mRNA) [38, 73, 272, 307-311], or proteins [49, 312] to deliver the factors to 
the somatic cells.  
3.3.3.1 Reprogramming via messenger RNA (mRNA) 
Reprogramming of somatic cells by mRNA was attempted by many groups [38, 73, 307, 313]. 
The process begins with the preparation of synthetic mRNA encoding for different factors by a 
process termed in vitro transcription (IVT) (Figure 14). RNA purification is achieved via spin-
column as well as DNase and phosphatase treatment. This removes any DNA in the mix as well 
as the 5’ triphosphates that can cause immunogenicity [38, 314]. The integrity of RNA is 
measured via agarose electrophoresis prior to transfection. A detailed protocol of mRNA 
induction of iPSCs with fibroblasts has been published by Mandal & Rossi [309]. mRNAs are 
then transfected into cell lines using Lipofectamine cationic lipid delivery vehicles [38, 313] or 
microporation [307]. Since mRNA is not self-replicating, transfection must be repeated. 
Although Plew’s study was unsuccessful in producing iPSCs with their OKSM[SV40] 
combination [307], Yakubov et al were successful in producing IPSCs with 5 transfections of 
mRNAs 24 hours apart with an efficiency of 0.05% (50 colonies/1x10
5
 cells)[313]. Warren et al. 
transfected for two weeks and had efficiencies of 2% (500colonies/2.5x10
4
cells) with OKSM and 
2.8% (700 colonies/2.5x10
4
 cells) with OKSML [38, 313]. Both groups were able to visualize 
iPSCs in approximately 2 to 3 weeks with higher efficiency then the OKSM retroviral methods of 
0.02% [37, 38, 313].   
This method has many advantages. Since there is no risk of integration, it favours the generation 
of genetically stable iPS cell lines. Furthermore there is no need for subclone isolation, or drawn 
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Figure 14 - RNA Production Flowchart 
To construct a template for RNA transcription reactions, the ORF of a gene of interest is first 
PCR amplified from a cDNA. Long oligonucleotides containing UTR sequences are then joined 
to the top strand of ORF amplicons by a thermostable DNA ligase, mediated by annealing to 
splint oligos which bring the desired single-stranded DNA (ssDNA) ends together. A T7 
promoter is incorporated in the 5’ UTR fragment. The ssDNA product is amplified using generic 
primers and TA cloned. A polyA tail is added with a PCR reaction using a T120-heeled reverse 
primer and the amplicons are used to template IVT reactions. Modified and unmodified 
nucleobases are used in the IVT reaction. An anti-reverse di-guanosine cap analog (ARCA) is 
included in the IVT reaction at four-fold higher concentration than guanosine triphosphate (GTP), 
as a result of which an estimated 80% of the product is capped. Spin-column purified IVT 
product is DNase-treated to eliminate the DNA template. Treatment with a phosphatase is used to 
remove immunogenic 5’ triphosphate moieties from the uncapped RNA fraction. The completed 
modified-RNA is then re-purified for use in transfections. (Reprinted from Warren 2010 with 
permission)[38] 
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out PCR evaluation of the iPSCs for integration. Even though it necessitates multiple 
transfections, it is relatively quick since it does not require any steps for treatment with 
antibiotics (such as DOX) or passages to allow dilution of exogenous factors. It is essentially a 
quick, simple, footprint free, efficient method of producing iPSC. Since Yukobov’s method does 
not use oncogene cMyc, it is more appealing to clinical work applications [313]. The prospect of 
using mRNA derived iPSCs in cell therapies has been made more realistic with the development 
use of mRNA in pre-clinical and clinical studies for cancer immunotherapy [315].   
3.3.3.2 Reprogramming Via Proteins 
Reprogramming of somatic cells can also be achieved using proteins [49, 165, 312]. This method 
relies on the in frame fusion of proteins coding regions with coding regions of cell-penetration 
peptide (CPPs) or protein transduction domains [316] that allows the protein to be incorporated 
into the cell. Zhou’s group created a system that would allow preparation of recombinant OSKM 
proteins by using the HIV transactivator of transcription (Tat)/poly-arginine system expressed in 
E.coli inclusion bodies [317-319]. Once solubilized, refolded and purified, the proteins were used 
to prepare a protein transduction media with which the somatic cells were treated overnight four 
times at 48 hour intervals. The group was successful in producing three colonies per 5 x 10
4
 cells 
(0.006%) when transduced with four factors, and one colony per 5 x 10
4
 cells (0.002%) but only 
when valproic acid (VPA) was included (VPA is a histone deacetylase inhibitor that will be 
discussed later)[49]. Without VPA, efficiency with OSKM proteins was reduced to 0.001% 
(13colonies/number of cells not provided)[312], however iPSCs were capable of being 
differentiated into dopaminergic neurons used in the treatment of Parkinson disease (PD)[320].  
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More recently, Nemes et al modified the HIV/arginine system by adding a nuclear localization 
signal (NLS) that would potentially increase nuclear localisation of the recombinant proteins and 
therefore reprogramming efficiency[165]. Transfection of cells was done four times on a 48 
interval as in Rhee’s study [320]. The experiments were performed on two types of mice, outbred 
(Imprinting Control Region (ICR)) mice and with inbred C57 black 6 (C57BL6) mice. Although 
both experiments yielded 8 and 6 primary iPSC colonies, respectively, only those stemming from 
outbred mice could be fully reprogrammed. These results indicate the importance of cell and 
species choice when studying iPSC technology for clinical applications. Although the 
reprogramming efficiency for Nemes studies could not be calculated, other studies show that 
reprogramming via proteins is less efficient and also takes longer for the appearance of iPSC 
colonies (on average 43 days)[49, 165, 312] than other methods. Efficiency aside, since the 
proteins eliminate the risk of DNA damage via integration, and genetic instability, as well as 
transgene reactivation, iPSCs derived via exogenous proteins expression are a safer source of 
cells for clinical applications.  
All the reprogramming methods discussed above focused on the delivery of exogenous 
pluripotency factors. Next we will discuss reprogramming via small molecules that target cellular 
changes and pathways to induce an embryonic stem cell state. 
3.3.4 Reprogramming Via Small Molecules  
An important part of the progress in the reprogramming of somatic cells has come from the study 
of the cellular processes that occur within the cells during this process. Time-based studies of the 
reprogramming process have allowed the elucidation of common gene expression patterns, and 
pathways that are upregulated or downregulated in a time sensitive fashion. From these studies, 
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scientists have been able to identify molecules and/or chemicals that can promote or inhibit 
pathways in order to enhance their reprogramming methods. Next, we will look at the cellular 
events of the different phases of reprogramming, as well as the small molecules that have been 
used to target these cellular mechanisms in order to enhance existing methods, or induce 
reprogramming on their own.  
3.3.4.1 Phases in Reprogramming 
A review by David & Polo in 2014 looked at different studies published on the creation of iPSCs 
from mouse embryonic fibroblasts (MEFs) using the classic OKSM factors [321]. Although this 
review was specific to mouse species, and OKSM factors, these types of studies give insightful 
information on possible commonalities of the internal cellular processes occurring which must be 
targeted in order to enhance reprogramming protocols. Their findings are summarized in Figure 
15 [321]. An explanation of these findings will be supplemented with recent data from other 
studies. Essentially, cellular processes leading to the reprogramming can be grouped into three 
phases; 1) Initiation: initial epigenetic and gene expression changes due to ectopic expression of 
OKSM factors, 2) maturation: a slow transition for preparation to independent pluripotency, and 
3) stabilization: activation of self-sufficient pluripotent cell populations [322]. Specific 
hallmarks, morphological features, transcriptome and cellular markers have been identified for 
each phase. Since time studies include specific time points (days post infection (dpi)), some 
reviews use time frames of 0-3, 3-9, and 9-12 days post induction (dpi) to represent the three 
phases [323, 324](Figure 15 and Figure 16, Panel A). Other studies have less defined time points, 
for example showing only changes occurring during the initial ten days of reprogramming [324, 
325] (Figure 16, Panel B).  
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      Days 0-3                      Days 3-9   Days 9-12 
 
Figure 15 - Phases in Reprogramming 
Sequential events occurring during somatic cell reprogramming. Markers and specific hallmarks 
of each phase of reprogramming are indicated. The iPSC transcriptome is acquired in two major 
steps. Abbreviations: Thy1: thymocyte antigen 1, Zeb1/2: zinc-finger E-box homeobox protein 1 
and 2, Snai1/2: small zinc-finger protein 1/2 , CD44: Cluster of differentiation 44 , MET: 
mesenchymal to epithelial transition, Alpl: alkaline phosphoatase, E-cadh: E-cadherin, EpCam: 
Epithelial cell adhesion molecules, SSEA1: species-specific embryonic antigen 1, ICAM1: 
Intercellular adhesion molecule 1 , Dppa4: Developmental pluripotency associated factor 4 , 
Pecam: Platelet endothelial cell adhesion molecule. (Modified from David 2014 with 
permission)[321]  
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Figure 16- Roadmaps of Epigenetic Reprogramming 
[A] Trajectory of reprogramming intermediates defined by Thy1, SSEA1, and Oct4-GFP (OGFP) 
expression (Polo et al., 2012). [B] Trajectories of reprogramming intermediates defined by 
CD44, ICAM1, and Nanog-GFP (NGFP) expression (O’Malley et al., 2013). Double lanes 
indicate transitions that occur at a higher frequency. iPSC, induced pluripotent stem cell; MEF, 
mouse embryonic fibroblast; MET, mesenchymal-epithelial transition; OSKM, Oct4, Sox2, Klf4, 
and cMyc. (Repinted from Theunissen & Jaenisch 2014 with permission)[324]   
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3.3.4.1.1. Initiation phase 
During the initiation phase, when transgenes are expressed, there is a general consensus that this 
ectopic expression of factors induces a change in endogenous gene expression patterns, more 
particularly for genes responsible for cell morphology, motility, signalling, proliferation, and 
metabolism [326]. The initiation phase is characterized by hallmarks like the loss of the somatic 
cell program, which has been shown to come about mostly by histone modifications as opposed 
to DNA methylation [323]. There is a redistribution of the H3K4 dimethylation (H3K4me2) 
associated with accessible DNA [327]. Furthermore, some cases included suppression of somatic 
marker genes (like thymocyte antigen 1(Thy1) and cluster of differentiation 44 (CD44)) via 
transcriptional repressive H3K27me3, and activation of pluripotency genes (AP and SSEA1 
(mice only)) via loss of suppressive H3K27me and gain of activating H3K4me3 [141, 277, 322, 
323, 325, 327, 328]. It has been postulated that OKS most likely bind to promoters of inactive 
DNA regions promoting activation of these regions, while cMyc likely binds to accessible, active 
somatic gene promoters to promote loss of somatic cell identity and promote the mesenchymal-
to-epithelial transition (MET) [329, 330], yet another hallmark of the initiation phase [331-333]. 
MET is demonstrated by the loss of expression of mesenchymal fibroblast TFs small zinc-finger 
proteins 1 and 2 (Snai1/2) and zinc-finger E-box homeobox proteins 1 and 2 (Zeb1/2) [141, 170, 
330] and the gain of expression of epithelial markers such as E-Cadh, epithelial cell adhesion 
molecule (Epcam), or miRNA-200 family [322, 334, 335].  
Other hallmarks of the initiation phase include the change in proliferation rate, closer to that of 
embryonic stem cells, which is accompanied by decrease in apoptosis and senescence markers 
[141, 331-333, 336, 337]. Shortly after reprogramming is initiated, the cell cycle p53 pathway is 
activated due to increase levels in p53, cell cycle inhibitor p21, and p16. Furthermore, there is a 
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decrease in levels of some cell cycle facilitators such as cyclin dependant kinase 1 (cdc2a or 
CDK1), cyclin B (Ccnb1), as well as cyclin dependant kinase 2 (Cdk2)[326](Figure 17). These 
changes in expression should lead to an increase in cell death and senescence. However increased 
levels of mouse double minute 2 (Mdm2), a p53 suppressor, and increase in cyclin D, a cell cycle 
facilitator, seem to counteract p53s effects and instead activate proliferation in reprogramming 
cells [212, 326](Figure 17). 
Metabolic shift is another hallmark of the initiation phase. Although some studies indicate that 
metabolic changes from oxidative phosphorylation to a more glycolytic pathway of energy 
production occurs in the initiation phase, other studies show that different metabolic changes 
occur at different time points in the process. For example, early reprogramming cells are most 
metabolically active at day 9pdi (late maturation) and decrease to a glycolytic/gluconeogenesis 
pathway in the pluripotent self-renewing iPSCs (late stabilization)[326, 338]. A study by Park et 
al showed that there was an increase in the expression of hypoxia-related genes early after 
induction which often correlates to a conversion to a more glycolytic, anaerobic metabolic 
pathway [326]. A more recent study has indicated that although both hypoxia inducible factor 1 
alpha (HIF1α) and HIF2α are necessary to initiate the metabolic switch, HIF2α can inhibit iPSC 
generation [339] in a manner that has yet to be elucidated. The initiation phase is one which most 
cells can complete, however the maturation phase is a bottleneck in the process of iPSC 
generation [340].  
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[A] Diagram depicting molecular mechanisms involved in regulating proliferation by various 
pathways. It explains the effect of key genes in the p53 pathway on proliferation. Blue boxes 
indicate Cdk activities during reprogramming while red boxes indicate Cdk activities in both 
reprogramming and final iPS cells. [B] Key DEGs and control modules of the p53 pathway affect 
cell cycle facilitation, cell cycle arrests as well as senescence & apoptotic sensitivity during 
reprogramming. ‘*’ and ‘**’ represent a change in expression of at least two-folds and four-folds 
over MEF respectively. Although p53 pathway activators (Cdkn1a, Cdkn2a and Trp53) undergo 
significant increase and some cell cycle facilitators (Ccnb1, Cdc2a and Cdk2) are down-
regulated, the constitutive increase in cyclin D and Mdm2 negates the effects of cell proliferation 
inhibitors in successfully reprogramming cells. (Reprinted from Park et al. 2014 with 
permission)[341] 
 
Figure 17 - Transitional Rewiring of Global Signaling Network during Early 
Reprogramming 
A 
B 
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3.3.4.1.2. Maturation Phase 
The major hallmark of the maturation process is the expression of endogenous 
pluripotency genes. Although analysis was performed differently (single cell transcriptomics 
followed by clonal analysis and fluorescent in situ hybridization (FISH) or FACs cell sorting), 
many studies have shown that cells acquire specific markers in a sequential way; Fbx15, Sall4, 
Oct4 in a first phase, then Nanog, and Esrrβ in a later stage [322, 323, 342, 343]. The cell surface 
marker intercellular adhesion molecule 1 (ICAM1) can also be identified during this later phase 
[325]. Studies done by Galipour showed the importance of endogenous Oct4 and NANOG 
expression in the preparation of transgene independency [277, 343] by their capability of binding 
promoters of inactive primary and secondary pluripotency-associated factors and inducing the 
DNA methylation changes characteristically seen in the stabilization phase [323].    
3.3.4.1.3. Stabilization Phase 
The changes that occur after iPSCs have acquired transgene-independent self-renewal and 
pluripotency are grouped together in the stabilization phase [81, 82, 277, 344]. This phase is 
marked by changes in DNA methylation patterns, due to changes in the expression pattern of 
methylation regulatory genes. These include: activation-induced cytidine deaminase (AID), 
deaminase apolipoprotein B mRNA editing enzyme catalytic polypeptide (Apobec), 5-
methylcytosine hydroxylase ten-eleven translocation 1 (Tet1), and DNA methyltransferases 3a 
and 3L (Dnmt3a, Dnmt3L). By changing inhibitory and activating methylation patterns, these 
enzymes allow the transcription of another wave of endogenous pluripotency markers such as 
Sox2, and platelet endothelial cell adhesion molecule (Pecam) (also known as CD31), and Dppa4 
[284, 322, 323, 342].  AID has also been shown to be involved in re-establishing the ESC 
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epigenetic memory in iPSCs [345, 346]. Other epigenetic changes such as telomere elongation 
and X-chromosome reactivation in female cell lines are visible in fully reprogrammed iPSCs 
[284, 347]. Other changes that may play a role in the transgene-independent self-renewal of 
iPSCs is the attenuation of p53, p21, and p16 levels, and the return of cell cycle facilitators levels 
(cdc2a, Ccnb1 (Cyclin B1), to their normal state,  allowing progression through the cell cycle 
[326].  
3.3.4.2 Reprogramming Via Small Molecules 
These time-based studies have allowed scientists to enhance reprogramming using small 
molecules or chemicals that can target pathways and hallmarks, thus increasing efficiency. They 
have also used small molecules in combination to replace one, two, three, or all reprogramming 
TFs. Small molecules can be categorized based on their function as: 1) epigenetic modifiers, and 
2) signalling modulators that target pathways and/or reprogramming hallmarks (MET, metabolic 
shift). Figure 18 depicts the roles of a multitude of small molecules in cellular reprogramming.  
3.3.4.2.1. Epigenetic Modifiers 
The first category of molecules consists of epigenetic modifiers. As seen previously, DNA 
methylation and hypermethylation is associated with the silencing of gene expression, while 
DNA demethylation is associated with reactivation of gene expression [141, 142]. In the case of 
reprogramming, studies have looked at increasing methylation of somatic genes and the 
demethylation self-renewal and pluripotency genes. Examples of molecules used to modify the 
epigenetic state include DNA methyltransferases inhibitors (DNMTi) like 5-Azacytidine
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Figure 18 - Small Molecule-regulated Reprogramming 
Small molecules are indicated by the white boxes, while their targets are in coloured boxes.  Arrow heads indicate activation while 
circles indicate inhibition. (Format reprinted from Su et al., 2013 with permission [348] and information from [73, 212, 214, 307, 322, 
336, 345, 346, 348-368] 
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 (5-aza-C) [119, 141, 369], 5-Aza-2’-deoxycytidine (5’aza-2’) [307], and RG108 [210, 352]. 
Tet1, a 5-methylcytidine (5mC) hydroxylase, has also been used to increase the efficiency of 
reprogramming. This enzyme works by hydroxylating the 5-methylcytidine at the Oct4 loci, 
which promotes its demethylation and reactivation during OSKM reprogramming. The use of this 
molecule has enabled the elimination of Oct4 in TSKM reprogramming [351]. Tet2 was also 
shown to induce the 5mC – 5-hydroxymethylcytidine (5hmC) conversion at the NANOG and 
Esrrβ loci to enhance somatic cell reprogramming [351]. Furthermore, treatment with Tet family 
members is believed to improve reprogramming by promoting 5mC – 5hmC conversion of the 
miRNA-200 cluster which plays an important role in the MET-associated transition of early 
reprogramming in fibroblasts [322, 351].  
Molecules that induce histone modifications and change accessibility of DNA have also been 
used to enhance reprogramming. Histone acetylation (usually on arginine or lysine residue) 
removes positive charges on the histone. This decreases the attraction between the histone and the 
negatively charged phosphate groups of the DNA backbone allowing for a more relaxed and 
accessible DNA for transcription [370]. Deacetylation allows DNA to return to a supercoiled 
heterochromatin essentially silencing transcription in this area [371]. Histone deacetylase 
inhibitors (HDI or HDACi) therefore allow for a more accessible DNA. HDACis used in 
reprogramming experiments include: sodium butyrate (NaB) [372], suberanilohydroxamic acid 
(SAHA), Trichostatin A (TSA) [353, 354] and VPA [206, 355]. 4-[(E)-2-(5,6,7,8-Tetrahydro-
5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid  (TTNBP), a retinoic acid receptor 
agonist which promotes histone acetylation, has also been used to enhance reprogramming of 
somatic cells [356]. 
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Another epigenetic change targeted is histone methylation. Histone methylation can be repressive 
or activating depending on the histone and the number of methyl groups added. Monomethylation 
such as H3K9me, H3K27me, H3K20me, H3K79me, and di or trimethylation of H3K4m2/3 are 
common activation methylations. Conversely, H3K9me2/3, H3K27me2/3, H3K20me3, and 
H3K79me3 are known inhibitory methylations [373, 374]. Rest compressor 2 (RCOR2), lithium 
chloride (LiCl), and Parnate (tranylcypromine), enhance reprogramming by inhibiting lysine-
specific histone demethylase 1’s (LSD1) activity [357, 358]. RCOR2 was used in conjunction 
with OKSM to increase efficiency to 0.47% producing 235 colonies for 5 x 10
4
 cells seeded. 
RCOR2 also eliminated the need for Sox2 in OKM reprogramming, albeit with lower efficiency 
[358]. 3-deazaneplanocin A (DZNep) and histone arginine methyltransferase inhibitor 5 (AMI-5), 
are two histone methyltransferase inhibitors (HMTi) that have been used to enhance 
reprogramming [356, 359].  G9a histone methylase inhibitor BIX [210] as well and H3K36 
demethylase Jumanji/ARID containing histone demethylation 1a and 1b (Jhdm1a/1b) [360, 375] 
have also been used to enhance reprogramming with one, two, or three of the original OKSM 
factors. Jhdm1a and 1b were found to enhance reprogramming by promoting Oct4 dependent 
expression of microRNA302/327 cluster responsible for regulating the cell cycle [360, 375, 376]. 
Interestingly, Shinagawa was able to produce iPSCs by using histone variants present in oocytes 
(testicular histone 2B and 2B (TH2A and TH2B)) in conjunction with Klf4 and Oct3/4. 
Efficiency was also 18 fold higher with TH2A and TH2B with OKSM, compared to their OKSM 
controls [361].  
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3.3.4.2.2. Signalling Modulators 
The next category of molecules used to enhance reprogramming is that of signalling modulators. 
These can target particular cellular pathways, their receptors or intermediates that are involved in 
reprogramming or specific hallmarks of the reprogramming phases. Transforming Growth 
Family Beta (TGF-β), Wingless-related integration (Wnt), Sonic Hedgehog (Shh), their ligands, 
and/or downstream effectors have been at the center of many studies. Since TGF-β pathway 
inhibits the epithelial-mesenchymal transition necessary in the early stages of reprogramming 
[334], molecules inhibiting the receptor or intermediates in the pathway have been used to 
overcome this obstacle and enhance reprogramming. These include 616452 (Repsox)[362], A83-
01 [207], LY-364947 [357, 364, 365], and activin-like kinase 4 (ALK4) receptor inhibitor 
compound B4 [212].  Lin et al were able to enhance OKSM reprogramming with the use of TGF-
β inhibitor SB431542 [208, 365], and mitogen activated phosphate kinase/Extracellular signal-
regulated kinase (MAPK/ERK) inhibitor PD0325901 [365]. Bone Morphogenic Proteins (BMPs) 
are members of the TGF-β family that promote MET during reprogramming [322], and have 
been shown to replace Klf4 and induce reprogramming when used with Oct4 alone to produce 
iPSCs [377]. Thiazovivin and Y27632, which are Rho-associated protein kinase inhibitors 
(ROCKi), have also shown to enhance reprogramming by promoting MET [38, 365-367]. 
CHIR, a glycogen synthase kinase-3 beta inhibitor (GS6K-3βi), enhances reprogramming by 
inhibiting the Wnt signaling pathway [357].  Other than CHIR, GSK-3βis Kenpaullone 
(KP)[363], compound B6 [212] and lithium chloride (LiCl) [360] have also been used in 
conjunction with OKSM factors to enhance reprogramming. Also notable, the activation of the 
Shh pathway via Shh, purmorphanime or oxysterol in conjuction with Oct4 was used to produce 
iPSCs with 0.11% efficiency [214]. Sarcoma (Src) family tyrosine kinase inhibitors such as 
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Dasatinib, iPY razine (iPY), protein phosphatase 1 (PP1) have been successful in replacing Sox2 
during reprogramming [364]. Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, 
Compound B8, an inositol triphosphate 3-kinase (IP3K) inhibitor, and Compound B10, a P38 
kinase inhibitor are all kinase inhibitors that have enhanced reprogramming [212, 377].  8-
Bromoadenosine 3’-5’-cyclic monophosphate (8-Br-cAMP), prostaglandin E2 (PE2), Forskolin 
(FSK), and Rolipram are all cAMP-dependent protein kinase activators [356, 378] that can target 
signalling pathways to promote reprogramming with at least 1 of the original OKSM factors.  
Metabolic shift has also been a target of small molecules used to enhance reprogramming. 
Fructose 2,6-bisphosphate (F2,6P) activates phosphofructokinase 1 (PFK1), an enzyme in the 
glycolytic pathway, inducing glycolysis directly. Targeting glycolysis indirectly through 
activation of hypoxia-inducible factor (HIF) pathway using hydroxylase inhibitors such as N-
oxalylglycine and Quercetin has also shown to enhance reprogramming efficiency. PS48, a 
3’phosphoinositide-dependant kinase (PDK)-1 activator enhanced reprogramming 15 fold, while 
PS48 and NaB (HDACi) enhanced reprogramming 25 fold compared to controls in Zhou’s study 
[207]. Other groups have produced iPSCs by using hypoxic growth conditions. Takahashi and 
Yamanaka’s group showed that hypoxic conditions could produce 2.5x – 3x the number of iPSC 
colonies by OKSM retroviral transfection and DOX-inducible PB transposon transfection of 
MEFs [75]. Panopoulous’s group noticed a 0.5 – 1.5 % increase in relative reprogramming 
efficiency in 5% oxygen conditions compared to 20% oxygen controls using OKSM retrovirus 
without and with TGFβi SB431532 [208].  
The use of ascorbic acid (VitC) has shown to improve efficiency when used with OKS [350], 
Jhdm1a/OS, Jhdm1a/O [368], or Jhdm1a/1b [375]. Jhdm1a is a histone demethylase that 
functions in a VitC dependent fashion to promote DNA accessibility [375]. VitC may also play a 
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role in the metabolic shift during reprogramming since its involvement in the regulation of 
gluconeogenesis in hepatic cells has already been confirmed [368]. VitCs enhancement 
capabilities may also stem from its ability to decreased p21 and p53 levels, allowing cell cycle 
progression and proliferation of cells [350]. Further investigations have also shown that ascorbic 
acid functions as a cofactor for Tet family members, promoting DNA demethylation and 
activation of the MET-associated miRNA-200 cluster, Oct4, NANOG, and Esrrβ loci, therefore 
enhancing reprogramming of somatic cells [322, 349, 379].  
3.3.4.2.3. Reprogramming Enhancement and de novo Reprogramming with Small 
Molecules 
Of all the categories of molecules, those that enhanced OKSM reprogramming the most were 
small molecules named compound 4 (a TGFβi), compound 6 (a GSK3βi), compound 8 (a PI3Ki), 
and compound 10 (a p38i) with efficiencies of 0.42%, 0.28%, 0.25%, and 0.25% respectively. 
CHIR (GSK3βi) enhanced OSK to its highest efficiency at 0.18% [357].  
Most of the experiments mentioned above used three or four OSKM factors; however some 
groups were able to produce iPSCs using one or a combination of small molecules with only 
Oct4 or no factors [207, 214, 355, 359, 379] with varying efficiencies. Oct4 in combination with 
binding to microtubules 1 (Bmi1) was shown to induce iPSCs with an efficiency of 0.17% [214]. 
Bmi1 is postulated to work by inhibiting cell cycle repressors p16, and apoptosis inducer p19. 
The same group replaced SKM using Sonic hedgehog agonists (oxysterol, purmorphanime or 
oxysterol) in combination with Oct4 to produce iPSCs with an efficiency of 0.11% [214]. Yuan 
et al were able to induce reprogramming with Oct4, A-83-01 (TGFβi) and AMI-5 
(methyltransferase inhibitor) with an efficiency of 0.02% [359]. Oct4 with a combination of VPA 
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(HDACi), CHIR (GSK-3βi), 616452 (TGFβi), and parnate (LSD1i) carried an efficiencies of 
0.05-0.08% (15-25 colonies/3x10
4
cells) in MEFs [355], while Parnate, CHIR, A8301 (TGFβi), 
PS48 (PDK1i), NaB (HDACi), and PD0325901 (MEKi) showed an efficiency of 0.0003% - 
0.012% (3 colonies/10
6
 cells – 23 colonies/2x104cells) depending on the human cell type [207].  
The use of VPA, CHIR, 616452, parnate, Forskolin (FSK), DZNep without and with TTNPB  
reprogrammed MEFS with efficiencies of 0.04 % (20 colonies/ 5x10
4
 cells) and 0.16%  (80 
colonies/5x10
4
 cells)[356]. Most impressively, RG108 (DNMTi) has shown to be able to 
reprogram mouse somatic myoblasts with an efficiency of 0.12% (57-60 colonies/5x10
4
cells) 
without any factors [352].  
Although in some cases, the addition of small molecules and chemicals did enhance the 
efficiency of reprogramming compared to the original Takahashi method (0.02%)[37], efficiency 
remained under 1%. The highest level observed was 0.42% with OKSM and compound 4 [212], 
followed by 0.18% using a combination of seven small molecules [356]. Although this is not as 
efficient as mRNA-mediated reprogramming (2.8%) [308], small molecules alone can reprogram 
somatic cells with higher efficiency than retroviral transfection of OKSM, and is comparable to 
the highest efficiencies obtained with viral (0.5%) [281] and plasmid vectors (0.9%) [186].  
Other advantages to using small molecules should be considered when choosing a method for 
iPSC induction. First and foremost, studies have shown that exposure of cell to exogenous 
OKSM factors via mRNA can be cytotoxic and therefore decrease the number of viable cells for 
reprogramming. This cytotoxic effect does not occur with the use of small molecules such as 
BIX, VPA, and 5’aza-2’  [307]. Therefore using small molecules could increase the amount of 
viable cells available for reprogramming. Furthermore, treatment of cells with small molecules is 
a much simpler process since there are no viral/plasmid vectors or mRNA preparation phases 
80 
 
 
needed. Small molecules are simply added to the media with which the cells are treated. 
Although initial appearance of ESC-like colonies may take somewhat longer (40 days vs. 7 to 30 
days via other methods), there is no clean up (excision of transgenes) phase necessary after 
reprogramming is complete, as small molecules are degraded by the cell, and also diluted out in a 
few passages. Again since small molecules are a footprint free method, PCR or Southern blotting 
experiments post-reprogramming to verify non-integration or excision of plasmids are not 
necessary. Lastly, there is lower risk of DNA damage with these methods since small molecules 
act on a signalling level, or on an epigenetic level to change expression patterns of endogenous 
pluripotency genes to induce reprogramming.  
It is evident that the use of small molecules in reprogramming is a vast field of study that is 
expanding. The next section will focus on the use of microRNA (miRNA) to enhance 
reprogramming or somatic cells.  
3.3.5 Reprogramming via microRNA (miRNA) 
Previous methods of reprogramming discussed focused on the ectopic expression of different 
transcription factors that have been identified as having important roles in pluripotency and self-
renewal such as OKSMLN [32, 48, 92], or targeting of cellular pathways and hallmarks that are 
recalled during reprogramming. The methods that will now be described are based on studies 
analysing microRNAs (miRNAs) levels within ESCs, iPSCs and somatic cells. miRNAs are 
small single-stranded non-coding RNAs approximately twenty-two nucleotides (nt) in length that 
regulate translation by binding to and targeting mRNAs for cleavage [380] or translational 
repression [381, 382].  Sometimes the DNA sequences of multiple miRNAs’ are found in the 
same genomic region and are therefore named as clusters or families [383]. Furthermore, it is  
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postulated that miRNAs with similar seed sequences function to have the same targets [335]. 
By comparing results from qPCR, northern blot, microarray and deep sequencing of ESCs and 
somatic cells, miRNAs associated with pluripotency, self-renewal, and differentiation have been 
identified [110, 384-387]. From miRNA analyses, scientists have been able to modify/enhance 
already existing reprogramming protocols as well as develop new individual protocols using 
miRNAs alone to produce iPSCs [192, 206, 388]. This next section will provide information on 
miRNAs responsible for pluripotency, self-renewal, and differentiation. It will further discuss 
miRNAs that have been used in somatic cell reprogramming.  
One study categorized hESC-enriched miRNAs into five major groups: miR-302, miR-17, the 
miR-371/373, as well as miR-130, and miRNAs from C19MC (chromosome 19 miRNA cluster) 
[335]. Each cluster contains at least two miRNAs stemming from the same chromosome (Table 
2).  Another group confirmed miR-302d role in ESCs and identified the miR290s cluster (miR-
290-295) as important regulators in ESCs [386]. Qi’s group also confirmed the role of miR-372 
and discovered the potential for miR-195 [387]. Although the roles of all miRNAs individually 
have not yet been elucidated, since the majority of them exert their function by acting upon cell 
cycle regulators, they have been termed ES cell-specific cell cycle-regulating (ESCC) miRNAs 
[387].  miR290s (particularly 291a-3p/294/295) and miR302d function by inhibiting G1/S 
transition inhibitors p21, retinoblastoma like 2 (Rbl2), and large tumor suppressor (Lats2) 
[386](Figure 19).  miR-17 (particularly 92b) promotes ESC proliferation by inhibiting the G1/S 
transition inhibitor p57 [389], while miR-195 was shown to target G2/M transition inhibitor 
WEE1 protein kinase [387]. Not only are the ESCC miRNAs upregulated by pluripotency genes 
Sall4, Oct4, NANOG, Sox2 and cMyc [390], miR-302s in particular stops epigenetic silencing of  
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Table 2 - Human Embryonic Stem Cell-Enriched microRNAs 
Members of microRNA (miRNA) families enriched in human embryonic stem cells (hESCs) as 
determined in our microarray profiling analyses are further annotated to describe in which 
chromosome they reside and their seed sequence (nucleotides 2–8 of miRNA). Highly similar 
seed sequences are similarly colored. All miRNA annotation data are obtained from miRBase, 
Release 14.0, September 2009 (http://microrna.sanger.ac.uk/)(Reprinted from Stadler 2010 with 
permission)[335] 
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Figure 19 - Role of miRNAs in ESC Self-Renewal, Proliferation and Differentiation 
ESCs express a unique signature of miRNAs whose transcription is regulated by a core 
pluripotency factors (Oct4, Sox2, Nanog). ESC-enriched miRNAs control the specific ESC cell 
cycle by targeting regulatory proteins involved in G1/S and G2/M transitions. ESC-enriched 
miRNAs maintain self-renewal capacities of ESCs as well as their pluripotency potential. 
Differentiated cells express miRNAs such as miR-145 and let-7 that target pluripotency factors 
and activate differentiation genes. Moreover, cell cycle inhibitors are expressed and cells exhibit 
a cell cycle dependent of the restriction point (R) (Modified from Mathieu et Ruohola-Baker 
2013 with permission)[376] 
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Oct4, Sox2 and Nanog by inhibiting DNMTs [391](Figure 19). C19MC are the least studied of 
the ESCC miRNAs, however it has been postulated that they may play similar roles in 
establishing ESC pluripotency and self-renewal as the other ESCC miRNAs since their seed 
sequence is quite similar [335]. 
Other miRNAs have been identified for their role in differentiation [386, 387, 392]. For example, 
miR-145 is significantly upregulated upon differentiation of hESCs [335]. miR-145 controls ESC 
differentiation by directly targeting the stem cell factors, thereby silencing the self-renewal 
program. Interestingly, miR-145 promoter is repressed by Oct4 in hESCs. Its loss therefore 
impairs differentiation and allows the expression of Oct4, Sox2, and Klf4 [393](Figure 19). 
miR200c, miR183 and miR203 have been identified as stemness-inhibiting miRNAs since they 
cooperate in the repression of pluripotency genes Sox2 and Klf4 and the expression of 
differentiation genes in differentiated cells [394], while miR134, miR296 and miR470 repress 
expression of Oct4, Sox2 and Nanog [395]. Mature lethal-7 (let7) miRNA is also responsible for 
expression of differentiation genes in differentiated cells, once Lin28 can no longer repress its 
conversion from an immature pre-let7 [396, 397]. Let7 is also responsible for suppressing Lin28, 
cMyc and Sall4 expression in differentiated cells [397](Figure 19).  
Since fully reprogrammed iPSCs have a similar miRNA profile as ESCs, scientists have also 
studied the expression of miRNA during the reprogramming process and noted that ESC- 
enriched miRNAs are expressed during the early phases of reprogramming [390, 392, 398, 399].  
Furthermore, since there is a functional link between miRNAs activation and Oct4, Sox2, cMyc, 
Lin28, Klf4, Nanog expression levels [390, 400], the role of miRNAs in reprogramming is of 
great interest. miRNAs have now been used in conjunction with other factors to enhance 
reprogramming [213] as well as on their own to  induce reprogramming [206, 217, 391] 
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 (Figure 20, Panel A).  
miR-200s and miR-205, usually triggered by the BMP pathway [322], enhanced reprogramming 
by inhibiting  Zeb1 and 2 mesenchymal-associated factor, therefore allowing expression the 
MET-associated marker E-cadherin [334, 401, 402](Figure 20, Panel B). Judson’s group studied 
the ability of miRNA-290 cluster (ESCC) to enhance reprogramming of MEFs by lentiviral 
vectors of OKSM factors [213]. The group co-transfected the miRNAs on day zero with other 
factors, then again on day 6.  Their results indicated that miR-291/3p, miR-294, and miR-295 
significantly enhanced reprogramming with the OKS factors[213]. Similar experiments showed 
that miR-302 and miR-372 clusters, enhanced OKS and OKSM retroviral reprogramming in 
human cells (Figure 20)[213, 403]. Subramanyam’s group further showed that human miR-302b 
and human miR-372 inhibit expression of genes that regulate the cell cycle (p21), and epithelial 
to mesenchymal transition (TGF-βRII), enhancing reprogramming by inducing proliferation and 
MET [403](Figure 20, Panel B). miR-106 and miR-93 have been shown to enhance OSK and 
OSKM reprogramming in the same way as miR-302 and miR-372 [399](Figure 20, Panel B). 
Liao’s study confirmed Subramanyam’s results and further showed that miR-302 and miR-367 
increase MET [404]. Lin et al’s group studied the epigenetic effects of miR-302s on 
reprogramming factors since this particular miRNA targets lysine-specific histone demethylases 
such as: amine oxidase family (AOF 1 and 2), LSD1, and methyl CpG-binding protein 
(MECP)[391]. The group was successful in producing iPSCs by transfecting human hair follicle 
cells (hHFCs) with a DOX-inducible plasmid vector containing the miRNA by electroporation. 
Further analysis by bisulfite DNA sequencing, immunostaining, and northern blotting showed 
that iPSC induction by miR-302 involved suppression of AOF2 which   
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Figure 20 - Functions of miRNAs in Cellular Reprogramming 
[A] Overview of the effects of miRNAs on iPSC formation. miRNAs beneficial for iPSC 
induction are represented in red while miRNAs shown to repress iPSC formation are in green. In 
orange are the microRNAs whose function has not been tested yet during reprogramming of 
somatic cells into pluripotent stem cells. [B] Mechanisms of action of miRNAs during the 
reprogramming process. OSK: Oct4, Sox2, Nanog. MET mesenchymal to epithelial transition. 
(Modified from Mathieu et Ruohola-Baker 2013 with permission)[376] 
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destabilizes DNA methyltransferase 1 (DNMT1) and inhibits its ability to methylate DNA. This 
demethylation enables activation of Oct3/4, Sox2, and NANOG transcription factors required for 
reprogramming [391](Figure 20, Panel B). Anokye-Danso’s  group also efficiently produced 
mouse (from MEFs) and human (from human foreskin and dermal fibroblasts) iPSCs by 
transfecting miRNA-302/367 via lentiviral vectors without other exogenous factors [206](Figure 
20, Panel A). Interestingly, reprogramming was successful in both species; however mouse 
somatic cells required the use of VPA. Furthermore, miPSCs showed positive results of viral 
integration, whereas the human hiPSCs did not. These two species-specific differences in the 
results reiterate the importance of species-specific studies in the field of iPSCs. This method 
reached an efficiency of 9.14 % (1600 colonies for 1.75 x 10
4
 cells seeded) with MEFs, and 11% 
(11579 colonies/10
5
 cells) with HDFs. It is the method that has the highest rate of efficiency thus 
far [206].  
While some group used ESC-enhanced miRNAs to enhance reprogramming, others looked at 
inhibiting differentiation-inducing miRNAs by antagomirs, genetic ablation, or antisense 
inhibitors to enhance reprogramming. For example, inhibition of miR-21 (TGFβ agonist) [169], 
miR-29 (p53 agonist)[173], miR-34 (p53 target)[405, 406], and Let-7 (LIN28 repressor) [397, 
407] were all shown to enhance OSK and OKSM reprogramming.   
These studies were successful in demonstrating that miRNAs can be used to enhance 
reprogramming or induce it on their own. The downfall to these past experiments is that they 
require the use of vector-based gene transfer to introduce the miRNAs which carry an inherent 
concern for integration. Miyoshi’s experiments addressed these concerns by transfecting mature 
double stranded miRNAs into mice and human cells at concentrations of 10–50 nM using 
Lipofectamine[217]. When transfecting all seven miRNAs (200c, 302a, 302b, 302c, 302d, 369-
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39, 369-5p), the group was able to reprogram mouse cells with an efficiency of 0.003% (5 clones 
for 1.5 x 10
5
 cells seeded), and human cells with an efficiency of 0.002% (2 colonies per 1 x 10
5
 
cells) [217].  The decreased efficiency with a direct miRNA transfection could possibly be due to 
the decreased expression of miRNA, or possibly to an increase HDAC activity in the cells since 
they were not treated with VPA as in Anokye-Danso’s method [206]. Testing this method with 
the addition of VPA would give a better indication of the efficiency differences between the 
Miyoshi and Anokye-Danso’s methods. Furthermore, although miR-200 clusters are ESC-
enhanced [335], and enhance MET in reprogramming cells [322, 334, 402], miR-200c has 
specifically been identified as a stemness-inhibiting miRNA by a different group [394]. miR-
200c may be responsible for the decrease in reprogramming efficiency. Even though efficiency 
was lower with the direct miRNA method, this method shows potential for clinical application 
since it does not show the same integration concerns as methods using viral or plasmid vectors 
[217].  
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3.3.6 Bacterial Reprogramming  
An interesting discovery was made in 2012 while a group was studying the influence of lactic 
acid bacteria (LAB) on cells other than those of the gastrointestinal epithelium, to which they are 
usually associated in a symbiotic fashion [408, 409]. The group incorporated LAB into human 
dermal fibroblast (HDF) cells by trypsinization and co-cultivation. The cells formed clusters 
within 2-3 days that resembled embryoid bodies formed from hESCs differentiation. Although 
the cells did not have proliferative capabilities, they had some of the characteristic features of 
hESCs and hiPSCs. They stained positive for ALP, NANOG, OCT3/4, SOX2 and SSEA-4. The 
clusters were multipotent, thus differentiating into cells of all three germ layers in culture, and 
when injected into immunodeficient mice. Authors speculate that the bacteria may be initiating 
reprogramming of HDF by secreting molecules that stimulate immune system activation, 
however further studies need to be completed to elucidate the mechanism. The efficiency of 
reprogramming was not noted in this study, however authors suggest that, with further research 
and development, bacterial reprogramming with symbiotic bacteria like LAB may present a safe 
alternative for producing cells needed for cell therapy [410].  
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Chapter 4 - Applications and Advantages  
As is the case with other stem cells, iPSCs have many applications. Their role in basic science, 
disease modeling, drug development and screening, toxicology testing as well as therapeutics will 
now be discussed.  
4.1 Basic Science 
iPSCs are of particular value in developmental biology research since they have the potential to 
differentiate into all cell types. For example their ability to differentiate into all types of 
pyramidal neurons made it possible to study cortical development in mice [411]. iPSCs have also 
been used in basic research to compare phenotypic differences between species. Marchetto et al 
explored the differences in gene expression profiles between humans and chimpanzees by using 
iPSCs generated from human dermal fibroblasts and frozen non-human primate tissues. Their 
objective was to elucidate evolutionary trends in gene expression that could explain the 
phenotypic differences between the two species [66].  
4.2 Disease Modeling 
An important use for pluripotent stem cells is disease modeling. Essentially, analysis of diseased 
cells (proteomic, transcriptomic, epigenetic etc.) and comparison to a normal control can help 
determine the underlying mechanisms of the disease. Elucidating the molecular mechanism of a 
disease can allow medical professionals to give a molecular diagnosis as well as a clinical 
diagnosis to their patients. Furthermore, gaining molecular insight about the disease can lead to 
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the development of appropriate target-based treatments. Prior to the discovery of iPSCs, hESCs 
were the most commonly used cells in disease modeling. ESC-derived diseased cells can be 
prepared by genetically modifying existing hESC lines, or by isolating pre-implantation embryos 
carrying the mutation of a genetic disorder [412-414]. The use of hESCs however is limited in 
disease modeling since genetic modifications have shown to be difficult, and embryos with pre-
implantation genetic diagnosis (PGD) only exists for monogenic diseases [415]. Furthermore, 
there is a very negative stigma attached to the use of cells that require the destruction of 
potentially viable embryos. Other cells that could be used for disease modeling include 
pathological somatic cells however they may be difficult to isolate from tissues and are difficult 
to maintain in culture [415]. 
 iPSCs have several advantages over hESCs as well as pathological somatic cells. Since they can 
be generated from a variety of easily accessible somatic cells (from blood, urine, and hair), they 
eliminate the need for invasive isolation of diseased cells (hepatocytes, neurons or others) and the 
destruction of embryonic material. Furthermore, iPSCs have been used to produce disease-
relevant cells to study monogenic disorders like epidermolysis bullosa [416], and more complex 
disorders such as Rhett syndrome [417] that ESCs have not been able to model. Using human-
specific diseased cells is also advantageous since previous studies have shown that the cellular 
mechanisms can be species-specific [51], and thus so can be the molecular mechanisms of 
diseases. One example of this is a study by Seok that showed that inflammatory response to 
tissue damage was quite different in mice than humans [418]. The use of human cells is 
important in elucidating the appropriate dysfunctional mechanism in order to target the disease 
properly. 
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There have been many diseases modeled using iPSCs since the first induction experiments. In 
2014, a review showed that there has been a dramatic increase in the amount of studies published 
on disease modeling with disease-relevant cells derived from iPSCs. From 2008 to 2011 there 
were 2, 7, 14, and 43 studies published respectively in disease modeling, while in 2012 and 2013 
there were 122 studies published on this topic. The most frequent diseases modeled were 
neurological (Alzheimer’s disease, Amyotrophic lateral sclerosis, spinal muscular atrophy, 
Huntington’s disease and Parkinson’s disease)(71 studies), cardiac (long QT syndrome 1, 2 and 
3, Catecholaminergic polymorphic ventricular tachycardia type 1 and 2)(26 studies), 
hematological (sickle cell disease, Fanconi anemia, Chronic myeloid leukemia)(23 studies), and 
metabolic (Wilson’s disease, Diabetes type 1&2)(18 studies). Other pathologies modeled include 
muscular (Duchenne muscular dystrophy) (6), ocular (Retinitis pigmentosa)(7), skin 
(Dyskeratosis congenita)(5), imprinting (Pradder-Willi syndrome)(2) conditions, and 30 other 
random diseases such as: Down syndrome (trisomy 21), Turner syndrome (monosomy X), 
Hutchinson Gilford Progeria Syndrome,  and Schizophrenia [419]. There has also been work 
done by Liu and Ding on modeling  tumors [420], and by Gamm et al on modeling retinal 
degeneration [421]. This review is a good indicator of the growing implication of iPSCs in 
disease modeling. Albeit the difficulty of establishing appropriate controls for disease modeling 
using iPSCs [415], many studies have been successful in recapitulating disease phenotypes [422]. 
One factor to be considered when using iPSCs in disease modeling is the choice of 
reprogramming method. Integrative methods could potentially cause genomic instability as well 
as change expression patterns within the cells. To decrease the possibility that results are caused 
by reprogramming itself, non-integrative methods should be used in disease modeling. 
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4.3 Drug Development and Screening 
Drug development and screening is another avenue for iPSCs use. In 2012, iPSCs-derived motor 
neurons generated from patients led to the discovery of a chemical compound capable of treating 
amyotrophic lateral sclerosis (ALS) [423]. A compound that could treat familial dysautonomia 
was also identified using patient-derived iPSCs [424]. Having human-based in vitro testing of 
drugs is important since previous studies have shown that the effectiveness of some medications 
can vary between species and even between individuals of the same species. For example, 
Lovastatin, a cholesterol-lowering agent was inefficient in rats, however proved quite successful 
in human clinical trials [425, 426].  
iPSCS can also be used in an even more specific manner in drug screening. Different drugs could 
be tested on patient-derived cells to determine the most efficient drug for each patient. With this 
information, researchers and medical practitioners can stratify clinical studies and trials into 
cohorts depending on the responses of each patient’s cells to different medications. When only 
one drug is available, in vitro testing of patient-specific cells allows identification of positive 
responders and elimination of non-responders prior to clinical trials.  Furthermore, analysis of 
non-responder’s cells can lead to the identification of possible molecular mechanisms of the lack 
of response, and elucidation of an appropriate target-based treatment opportunity for the non-
responder group. This was done in the clinical study of the effects of VPA on patients with spinal 
muscular atrophy [427]. The group performed microarray analysis on neurons derived from 
patient-specific iPSCs and compared gene expression profiles of their responders to those of their 
non-responders. From this, they identified an increase in the expression of a fatty acid translocase 
enzyme (FAT/CD36) in non-responders compared to responders. The group then showed that 
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CD36 was indeed responsible for the non-responsiveness of the cells to the VPA [427]. Lastly, 
once drugs have been tested for efficiency, dose-response parameters can also be established for 
pre-clinical work. Implications of iPSCs in drug development and screening can increase success 
rates of clinical studies and trials, and therefore improve patient outcomes.  
Patient-specific iPSCs could also serve in toxicity testing of non-target cells. Essentially, scientist 
can produce a variety of somatic cells (like neurons, cardiomyocytes, and hepatocytes) to test 
drug toxicity levels on these non-targets in pre-clinical trials. Not only can this provide 
information on toxic drugs, but it can also help determine the appropriate dosage for treatment in 
a patient-specific manner. Although hiPSCs-derived cardiomyocytes for pharmaceutical 
cardiotoxicity testing were made commercially available in 2011 [428], their characterization is 
still ongoing [429]. Since toxicity may be patient-specific, it may be wise to do toxicity testing on 
a patient to patient basis.  It is clear that iPSCs can be a definite asset in drug toxicity testing 
during pre-clinical trial development.   
4.4 Therapeutics  
A growing field for iPSC technology is their use in therapeutics, like regenerative medicine or 
cell therapies. The hope is to be able to generate iPSC-derived somatic cells that would be 
injectable into the patient tissues in order to regenerate and have some kind of restorative effect 
on the function of the tissue. One big advantage of using patient-derived iPSC-derived cells 
(autologous) over ESCs-derived cells (heterologous) is that they decrease the risk of rejection of 
the cells or tissues. Although early studies showed that undifferentiated iPSCs injection in vivo 
can stimulate an immune response [77, 430], further studies showed that differentiated cells of 
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iPSC origin did not have the same fate [431, 432]. Furthermore, pre-clinical models have shown 
that iPSC-derived somatic cells can be transplanted without immune rejection [433, 434]. 
Although it is not patient-specific, since iPSCs can be banked like ESCs, an “iPSC stock project” 
was authorized to bank iPSC lines for future use with histocompatible donors with no other 
transplant options [435].  
One concern to be addressed prior to using iPSC-derived cells in cell therapies is their 
tumorigenic potential. It is well known that iPSCs produce teratomas once injected into a host as 
well as tumors in pups from germline competent iPSCs injected into blastocyst. Scientists have 
suggested that this may be due to the proliferative nature of the cells, the use of oncogenes during 
reprogramming or the genetic instability caused by integrative methods [32, 48]. What has been 
debated is wether or not the differentiated cells obtained from iPSCs are tumorigenic. There is 
hope that this is not the case since iPSC-derived cardiomyocytes showed no sign of 
tumorigenicity after injection into SCID mice [436]. It was made clear by this study that 
differentiated cells must be carefully purified prior to injection, since non-differentiated and 
unpurified cells were shown to produce tumors [436]. It will be imperative that iPSC-derived 
cells follow rigorous tumorigenicity testing prior to use in therapeutic clinical trials [437, 438]. 
Since the first induction experiments, many cell-based pre-clinical studies have been conducted 
using iPS-derived cells. The first was in 2007 for the treatment of sickle cell anemia [439]. Table 
3 summarizes some of the most notable pre-clinical studies done thus far, the disease implicated, 
the iPSC derivatives, as well as the restorative effect of transplantation. These include recovery 
of Parkinson’s disease symptoms [320, 440-442], improved muscular function in muscular 
dystrophy [443], and enhanced recovery of motor function in spinal cord injuries [444], as well 
as activity of photoreceptors in age-related macular degeneration and retinitis pigmentosa [289].   
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Table 3 - Preclinical Studies Using iPS-Derived Cells in Cell-based Therapeutic Approaches 
(Reprinted from Lázaro et al., 2014 with permission)[256] 
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The last study mentioned above has led to the approval of the first human clinical study using 
iPSC derivatives that is being led by Dr. Masayo Takahashi at the RIKEN Center for 
Developmental Biology in Kobe Japan [445]. The group produced iPSCs by transfecting human 
dermal fibroblasts of patients with age-related macular degeneration with the SeV harbouring the 
four Yamanaka factors. In a two-step process, iPSCs were differentiated into retinal pigment 
epithelium (RPE) by exposure to Left-right determination factor A (Lefty A), Dickkopf WNT 
signalling pathway inhibitor 1 (Dkk1), and Activin A, then into RPE with photoreceptor 
capabilities with exposure to Taurin, Shh and retinoic acid [289, 446]. Sheets of cells are then 
transplanted into the eye to restore vision.  
The first patient received her transplantation in September of 2014, however in July of 2015, it 
was announced that the clinical study had to be put on hold after the second patient’s cells did not 
pass the genetic stability testing needed for transplantation [447, 448]. Although this news may 
have been a shock to some, from the information presented in this review about the disadvantages 
of using pluripotency factors, and viral systems for reprogramming, it is not surprising that the 
cells transfected with OKSM SeV developed genetic mutations. The nature of the genetic 
instability is not quite clear since one reference states that the mutations that the cells have 
suffered were induced by the reprogramming process [447], while another states that it is unclear 
if it was a pre-existing somatic cell mutation [448]. It is an unclear future for the study since it is 
unknown as of yet if Dr. Takahashi will work on generating patient-specific iPSCs by a different 
method or simply continue using the allogeneic cell lines that are being produced in Yamanaka’s 
lab [449].  
This new development in the world of iPSC technology demonstrates the importance of stringent 
validation testing during these clinical studies as well as the importance of focusing time and 
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energy on developing effective reprogramming methods that will generate genetically stable 
iPSCs that are safe to use in a clinical setting. Many groups still use the original factors, two of 
which are oncogenic.  Furthermore integrative techniques, although useful in achieving high 
exogenous gene expression, could cause genomic instability and mutations in the host DNA. The 
use of non-integrative methods, non-oncogenic factors, such as small molecules and/or miRNA 
may prove to be better options for generating iPSCs that will later be used in therapeutics.  
Another component of iPSC generation that has not been discussed is the feeder layer of cells. 
Mouse embryonic fibroblasts are the most commonly used feeder cells for human iPSC 
generation; however this could be a possible source of contamination for cells that need to be 
histocompatible. Many groups have shown that iPSCs can be successfully generated without a 
MEF feeder layer, using synthetic xeno-free media with different induction methods [185, 308, 
450, 451]. Specific protocols for integration free, xeno-free reprogramming would have to meet 
the Good Manufacturing Practice and clinical-grade requirements prior to clinical trials [377, 
452, 453]. Furthermore, the same Good Manufacturing Practice status for differentiation and 
isolation protocols would need to be achieved prior to the use of iPSC-derived cells in cell-based 
therapeutic clinical trials.   
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Chapter 5 – Conclusion  
It is clear by this review that the generation of induced pluripotent stem cells less than ten years 
ago was a considerable factor in many discoveries that would not have been possible with the use 
of other stem cells.  Their induction has also allowed for the expansion of another branch of cells 
which have been used in many applications in basic science research, disease modeling, drug 
development and screening, toxicology testing as well as therapeutics. 
In the past nine years, significant efforts have been made to properly characterize iPSCs and 
understand the cellular mechanisms of the reprogramming process to elucidate more efficient and 
safe induction methods.  From many of these studies, particularly the results of the first human 
clinical study, it is clear that some methods still carry safety concerns that need to be addressed 
prior to their use in human clinical trials.   
Although the elaboration of a plethora of different techniques from different groups has led to 
progress in cell choice, efficiency and safety, the lack of consistency in methods has also 
increased the challenge to produce a standard reprogramming protocol that can be applied to all 
cell types for all cell applications. Scientists have been able to analyse reprogramming cells with 
time-scale studies, as well as completely reprogrammed cells in order to elucidate what cellular 
mechanisms have been turned on and off to allow reprogramming; for example, the decrease of 
expression of somatic-related genes and increase in expression of pluripotency-related genes, as 
well as the epigenetic changes needed to allow these modifications to occur in the cells. 
However, they have not been able to explain the minimal requirements needed for cellular 
reprogramming, nor why only such a small percentage of cells (under 1% in most studies) 
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actually reprogram. This leaves the scientific community with many questions about the 
reprogramming process and the use of iPSC-derived cells. Why are only certain cells 
reprogramming?  If the cells are all of the same type, why are they not all transforming 
uniformly? What is particular to the cells that can successfully reprogram from those of the same 
colony that cannot reprogram? It can be postulated that only those cells that are unable to protect 
themselves against these foreign substances will be able to reprogram. It is also possible that only 
the cells that have been subjected to the appropriate factors or molecules in a specific order, or in 
sufficient amounts will be susceptible to this internal rewiring. These theories have yet to be 
verified or even truly examined. To date, there is no magic formula for producing iPSCs. The key 
to reprogramming has not been elucidated.  
There may never be a magic formula to reprogramming, however elucidation of the minimal key 
components that need to be triggered in the cell, regardless of cell type, need to be discovered if 
reprogramming efficiency is to be increased significantly. In order to achieve this result, broad-
scale transcriptomic, epigenetic, and proteomic analyses will need to be conducted on iPSCs 
derived from different cell types.  Furthermore, it will be of primordial importance that time, 
energy, and funds be spent on performing these analyses on iPSCs that have been reprogrammed 
by methods that have shown to pass all appropriate validation (genetic stability) and safety 
criteria. It would be an unfortunate waste for scientists to be using techniques that could affect the 
validity of their results or would limit the use of cells later on. Since there are multiple elements 
that still need to be addressed in iPSC technology, it is unclear if or when a safe, efficient, 
comprehensive method for achieving reprogramming of somatic cells will be developed.  
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